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SAMMENDRAG 
Molekylær og funksjonell karakterisering av brystkreft gjennom kombinasjon 
av MR-avbildning, genuttrykksanalyse og metabolsk profilering 
 
Brystkreft er den hyppigst forekommende kreftformen hos kvinner i Norge. 
Sykdomsutfallet er svært varierende. Noen pasienter har langsomt voksende tumorer 
som holder seg i brystkjertelen, mens andre har aggressive tumorer som vokser raskt 
og gir metastaser. Basert på genuttrykksprofiler har brystkreft blitt delt inn i minst 
fem undergrupper med ulike kliniske egenskaper og prognose. En bedre forståelse av 
egenskapene til de ulike undergruppene og hvordan de best kan behandles er 
nødvendig for å dra nytte av denne molekylære klassifiseringen i diagnostikk og 
behandling av brystkreft.  
 
Motivasjonen for arbeidet i denne avhandlingen har vært å kartlegge forskjeller i 
brystkreftsvulstenes metabolisme og vaskularisering ved hjelp av magnetisk resonans 
(MR) avbildning og spektroskopi. Arbeidet viser hvordan ulike MR-metoder kan 
brukes til å studere biologien i to dyremodeller av brystkreft som representerer de 
molekylære undergruppene luminal-like og basal-like brystkreft. Resultatene viser 
ulike MR-karakteristika i de to brystkreftmodellene med henholdsvis god og dårlig 
prognose.  
 
MR-spektroskopi kan brukes til å studere metabolisme i celler og vev. Siden 
kreftceller har et stort behov for energi og byggeklosser for å kunne vokse raskt, har 
de metabolske egenskaper som avviker kraftig fra friske celler. I dette arbeidet er det 
påvist forskjeller i kolinmetabolisme mellom luminal-like og basal-like 
brystkreftxenografter, og metabolittmønstrene fra dyremodellene er representative for 
funn i kliniske prøver. Siden kolinforbindelser ofte brukes som tumormarkør både i 
diagnostikk og vurdering av behandlingsrespons, kan forskjell i kolinmetabolisme 
mellom ulike molekylære undergrupper ha klinisk betydning. I avhandlingen er det 
også beskrevet hvordan glukosemetabolismen kan studeres ved hjelp av 13C-anriket 
glukose. Bruken av en stabil, MR-detekterbar isotop gjør det mulig å måle hvor raskt 
glukosen omdannes til andre metabolitter som laktat og alanin, og hvorvidt glukosen 
er et substrat i sitronsyresyklus. Unormal glukosemetabolisme er et vanlig kjennetegn 
 
 
i kreft, og utnyttes klinisk blant annet i PET-avbildning. Det er også stor interesse for 
hyperpolarisert MR-spektroskopi i måling av laktatproduksjon i kreft. Metoden som 
er etablert i dette arbeidet gjør det mulig å studere metabolisme ex vivo og å studere 
sammenhengen mellom genuttrykk og metabolismehastighet. I dyremodeller av 
luminal-like og basal-like brystkreft ble det vist at den minst aggressive modellen 
hadde raskest glukoseomsetning, noe som tyder på at veksthastighet og aggressivitet 
ikke er direkte knyttet til glukosemetabolisme i dyremodeller av brystkreft. 
 
MR-avbildning kan brukes til anatomisk avbildning av kroppen, men også til studier 
av funksjonelle egenskaper som blodgjennomstrømning og celletetthet. I kreftsvulster 
er blodårene ofte uferdige og dårlig organisert. Uten tilstrekkelig blodtilførsel 
begrenses tumorveksten, og tumorcellenes evne til å stimulere til innvekst av nye 
blodkar (angiogenese) har betydning for sykdomsutfallet. Ved hjelp av 
kontrastforsterket MR-avbildning ble vaskularisering og nydannelse av blodårer 
studert i dyremodellene av luminal-like og basal-like brystkreft. Ved hjelp av 
dynamisk kontrastoppladet MR-avbildning og immunhistokjemi ble det vist at 
modellen av basal-like brystkreft har et større kontrastopptak, at den er bedre 
vaskularisert og at den har mer aktiv angiogenese enn modellen av luminal-like 
brystkreft. I en oppfølgingsstudie ble effekten av antiangiogenese-legemidlet 
bevacizumab studert. Dette stoffet hemmer nydannelsen av blodkar og kan derfor 
begrense tumorveksten. Kort tid etter behandling viste MR-avbildning en økt 
kontrastoppladning. Immunhistokjemi viste en reduksjon i blodåretetthet og 
nydannelse av blodkar. Dette ble tolket som en normalisering av blodårene i tumor og 
bedret vaskulær funksjon, noe som kan ha betydning for bruken av bevacizumab 
sammen med andre cytostatika eller stråleterapi. 
 
Avhandlingen består av fire arbeider som alle dreier seg om bruk av MR i 
dyremodeller av luminal-like og basal-like brystkreft. I de to første arbeidene har 
høyoppløst ex vivo MR-spektroskopi blitt brukt i kombinasjon med 
genuttrykksanalyse for å beskrive tumorspesifikke metabolske egenskaper. I de to 
siste arbeidene har dynamisk kontrastoppladet MR-avbildning og farmakokinetisk 
analyse av kontrastmiddeldistribusjon blitt brukt til å beskrive tumorenes 
vaskularisering og hvordan denne endres ved antiangiogenesebehandling. Felles for 
de fire arbeidene er at de beskriver hvordan ulike MR-teknikker kan skille mellom 
brystkreftmodeller av ulik aggressivitet. De viser også hvordan MR-parameterne kan 
beskrive molekylære og strukturelle forhold i tumorene. Avhandlingen kan derfor 
bidra til økt forståelse av MR-funn i diagnostikk og behandling av brystkreftpasienter. 
I tillegg danner den et solid fundament for videre studier i de studerte dyremodellene 
av luminal-like og basal-like brystkreft, særlig med tanke på identifisering av nye 
behandlingsregimer og bruk av MR-avbildning i vurdering av behandlingsrespons. 
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SUMMARY
Molecular and functional characterization of breast cancer through a 
combination of MR imaging, transcriptomics and metabolomics 
 
Breast cancer is the most frequent cancer among women in Norway. The outcome of 
this disease is heterogeneous. Some patients have slowly growing tumors which stay 
confined within the mammary gland, whereas others have aggressive tumors that 
grow rapidly and metastasize to distant tissues. Based on gene expression profiles, 
breast cancer has been divided into at least five different subtypes with differences in 
clinical characteristics and prognosis. Improved understanding of the biology of these 
subtypes and how they should be treated is needed to benefit from this molecular 
subtyping in breast cancer diagnosis and treatment.  
 
The motivation for this work has been to map differences in breast cancer metabolism 
and vascularization using different MR imaging and spectroscopy methods. The work 
shows how different MR methods can be used to study the biology of animal breast 
cancer models representing the molecular subgroups luminal-like and basal-like 
breast cancer. The findings represent MR characteristics in breast cancer with good 
and poor prognosis, respectively.  
 
MR spectroscopy can be used to study metabolism in cells and tissues. Since cancer 
cells have a large need for energy and molecular building blocks in order to grow fast, 
they have metabolic properties that differ markedly from healthy cells. The thesis 
describes how MR-spectroscopy can detect differences in choline metabolism 
between luminal-like and basal-like breast cancer, and demonstrates how metabolic 
patterns found in the animal models are representative for findings in clinical samples. 
Since CCCs are proposed as biomarkers in diagnosis and evaluation of response to 
therapy in breast cancer, differences in choline metabolism between different 
molecular subtypes may be of clinical relevance. 
The thesis also describes how glucose metabolism can be studied using 13C-labeled 
glucose. Using a stable, MR-detectable isotope allows assessment of the metabolic 
fate of glucose. Abnormal glucose metabolism is a typical feature in cancer, and is the 
basis for PET imaging using FDG. There is also great interest for use of 
 
 
hyperpolarized MR spectroscopy for measurement of lactate production in cancer. 
The method that is established in this work allows ex vivo studies of metabolism and 
the relationship between gene expression and metabolic rates. In the luminal-like and 
basal-like animal models, it was found that the least aggressive model had the highest 
glycolytic rate, suggesting that tumor growth rate and aggressiveness not necessarily 
is directly linked to glycolytic rate.  
 
MR imaging can be used for anatomical imaging of the body, but also for studies of 
functional properties such as perfusion and cellular density. In tumors, the blood 
vessels are typically leaky, poorly organized and have suboptimal function. Without 
sufficient blood supply, tumor growth is limited. The tumor cells’ ability to stimulate 
growth of new vessels has impact on disease outcome. Vascularization and 
neoangiogenesis was studied in the luminal-like and basal-like models.  Using 
dynamic contrast-enhanced MR imaging and immunohistochemistry, it was found 
that the basal-like xenograft model had higher contrast uptake, that it is better 
vascularised and has more active angiogenesis than the luminal-like xenograft. In a 
follow-up study, the effect of the antiangiogenic agent bevacizumab was studied. This 
drug inhibits the formation of new blood vessels and can therefore slow down tumor 
growth. Shortly after treatment, MR imaging demonstrated increased contrast agent 
uptake in the tumors. Immunohistochemistry showed a reduction in the number of 
microvessels and angiogenic activity. These findings were interpreted as 
normalization of blood vessels and improved vascular function. MR imaging of 
vascular normalization may have impact on the use of bevacizumab together with 
other cytotoxic drugs or radiotherapy.  
 
The thesis consists of four papers which all describe use of MR in animal xenograft 
models of luminal-like and basal-like breast cancer. In the two first papers, high 
resolution ex vivo MR spectroscopy has been combined with gene expression analysis 
for description of tumor-specific metabolic properties. In the last two papers, dynamic 
contrast-enhanced MR imaging and pharmacokinetic analysis of contrast agent 
distribution has been used to describe tumor vascularization and how this respond to 
antiangiogenic treatment. All four papers describe how different MR techniques can 
distinguish between animal models of varying aggressiveness. They also show how 
the MR parameters are associated with molecular or structural properties of the 
 
 
tumors. The thesis may therefore contribute to improved understanding of MR 
findings in breast cancer diagnosis and treatment. In addition, it forms a basis for 
further studies of these animal xenograft models of luminal-like and basal-like breast 
cancer, especially with regard to identification of new treatment regimens and MR 
imaging for therapy response monitoring.  
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1 Introduction
 
1.1 Cancer
Cancer is a group of diseases typically characterized by rapid and uncontrolled 
division of cells. Depending on their origin, these cells can be present as disseminated 
in body fluids or form solid tumors. In malignant tumors, the abnormal growth of 
cells is accompanied by invasion of neighboring tissue and spread of cancer cells to 
distant locations (metastasis). Cancers can arise from a wide range of cell types and 
organs, and the degree of malignancy varies both between cell types and within 
cancers arising from the same cell type. This variation is reflecting the underlying 
genetic abnormalities that cause cancer. A wide range of cancer-promoting 
abnormalities in the genetic material cells can cause cancer. Such abnormalities can 
occur both in single genes and in combinations of several genes, but are typically 
related to the cell’s ability to replicate, its ability to avoid death, and its ability to 
interact with surrounding tissue.  
 
Cancer is a major source of morbidity and mortality both nationally and globally. In 
2008, global estimates included 12.7 million new cancer cases and 7.6 million cancer 
deaths (Ferlay 2010). Through organized efforts in cancer prevention and treatment, 
these numbers could be significantly reduced. Still, there is a large unmet medical 
need for earlier diagnosis, better risk prediction and treatment of cancer. Treatment 
options include surgery, radiation therapy and chemotherapy/hormonal therapy. 
Optimal treatment of the disease is important not only for individual patients but also 
for socio-economic reasons. In recent years, treatment has become increasingly 
personalized, meaning that the biologic features of individual cancers are taken into 
account when selecting treatment strategies.  
 
Further understanding of the genetics of cancer will hopefully aid in development of 
new drugs targeting genetic abnormalities. Stratification of patients into increasingly 
smaller subgroups that can be managed and treated based on specific disease and risk 
profiles will also expectedly improve today’s standards of cancer management.  
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1.2 Breast cancer 
Worldwide, breast cancer is the most frequent cancer type in women, and causes more 
than 400.000 deaths per year. In Norway, approximately 2700 cases are diagnosed 
each year (Bray 2009). It is characterized by highly variable progression, from rapidly 
growing tumors with early distant metastases to slowly growing tumors that do not 
spread from the mammary gland. The prognosis has continuously improved through 
several decades, which could be associated with both the introduction of screening 
programmes and better treatment (La Vecchia C. 2010). In Norway, the 5-year 
survival without signs of relapse is more than 80% (Bray 2009). Still, breast cancer is 
a leading cause of lost life-years in women. The prognosis of the disease depends on 
the stage at the time point of diagnosis, and the 5-year survival in patients who are 
diagnosed with metastatic breast cancer is below 20% (Bray 2009). Thus, current 
research tends to focus on treatment options for the most aggressive forms of breast 
cancer.  
1.2.1 Breast cancer classification 
Breast cancer is a highly heterogeneous disease, and classification systems have been 
constructed to account for morphological, functional and molecular differences. In 
accordance with the theory of step-wise acquisition of malignant phenotype, breast 
cancer present in the range from dysplastic lesions to distal metastatic disease. Most 
malignant breast tumors are carcinomas, of which ductal and lobular carcinomas are 
the most frequent morphological subtypes. Breast cancer metastasis most frequently 
occur in axillary lymph nodes due to local lymphatic transport of tumor cells. Distant 
metastases show high affinity to bone, lung, brain and liver tissue.  
Clinically, tumors are staged according to their size, lymph node involvement and 
metastasis status using the TNM (tumor, node, metastasis) system (Singletary 2003). 
Depending on these characteristics, breast tumors are classified as primarily operable 
or primarily inoperable.  
Histological evaluation of breast tissue includes description of premalignant 
conditions such as lobular and ductal hyperplasia, where more than two cell layers are 
present in these structures. In addition, atypical features such as enlarged cell nuclei 
may be observed. If the hyperplastic lesions have high proliferative rate and high 
degree of atypic features, the lesion may be termed a ductal/lobular carcinoma in situ 
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(DCIS/LCIS). In these conditions, the cancer cells are confined to the ductal/lobular 
lumen. If cancer cells have penetrated the basal membrane, the lesions represent 
invasive breast cancer. The histological examination of breast cancer also includes an 
assessment of tumor grade, which depend on parameters such as cellular 
proliferation, variation in nuclear size and shape, and the degree of differentiation in 
the tumor tissue. High proliferation rate, poorly differentiated cells and large nuclear 
variation are associated with high tumor grade and indicate a poor prognosis.   
 
1.2.2 Estrogen/progesteron receptor expression and HER-2 
overexpression  
In addition to anatomical and morphological classification, histopathological 
evaluation of breast cancer includes assessment of hormone receptor status and 
human epidermal growth factor 2 (HER-2) status. The presence or absence of 
estrogen receptor (ER), progesterone receptor (PgR) or HER-2 has consequences for 
choice of treatment, as hormone blocking therapy (tamoxifen, aromatase inhibitors) or 
HER-2-blocking antibodies (trastuzumab) should be administered only to patients that 
express these receptors.  
Approximately 70-75% of all breast cancers express either estrogen receptor (ER) or 
progesterone receptor (PgR) (Osborne 1998). The importance of circulating estrogen 
levels in breast cancer was acknowledged in the 19th century, when ovariectomy was 
shown to induce regression of primary breast carcinomas (Beatson 1896). Activation 
of hormone receptors lead to transcription of a number of genes involved in cell 
proliferation (Osborne 2005). In patients with hormone-receptor positive tumors, 
endocrine therapy is therefore an attractive treatment strategy with proven efficacy 
and favorable side effect profile (Johnston 2010). Drugs used in endocrine therapy 
are designed to inhibit ER/PgR activity, either by reduction of circulating estrogen 
levels or by blocking the hormone receptors.  
 
The epidermal growth factor receptor HER-2 is overexpressed in 20-30% of breast 
cancers. Activation of this receptor can trigger downstream signalling cascades 
resulting in effects on cancer cell proliferation, differentiation, adhesion and 
migration (Harries 2002). HER-2 overexpression is predominantly caused by 
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amplification of the Her-2 gene, and is associated with poor prognosis. However, 
development of the anti-HER-2 antibody trastuzumab (Herceptin®) has provided an 
attractive treatment alternative for this subset of breast cancer patients (Slamon 
1989).  
 
1.3 Breast cancer treatment 
The major clinical treatment decision in breast cancer is whether or not the tumor 
should be surgically removed. Therefore, the staging system plays an important role 
in breast cancer management. Depending on tumor stage, chemotherapy can be used 
to prevent cancer recurrence following surgery (adjuvant therapy), to shrink a tumor 
prior to surgery (neoadjuvant therapy) or to slow down the progress of inoperable 
disease. In Norway, treatment guidelines and algorithms for different scenarios are 
recommended by the Norwegian Breast Cancer Group (NBCG). Typically, several 
treatment modalities such as surgery, radiotherapy and adjuvant chemotherapy are 
combined for the best possible outcome. 
Localized disease is always treated with curative intention. Surgical resection of the 
tumor and, if necessary, infiltrated lymph nodes, is the treatment of choice. This is 
usually combined with radiation therapy and/or adjuvant chemotherapy. 
 
Approximately 10% of breast cancer patients are diagnosed with locally advanced 
breast cancer, due to large tumor size (T3-T4) or metastases to axillary lymph nodes 
(N”-N3) but no distant metastasis. These patients are defined as primary inoperable, 
and neoadjuvant chemotherapy is often considered.  The intention of this treatment is 
to reduce the tumor size, thereby allowing surgical removal of the tumor. Currently, 
there is a trend to include patients with primary operable tumors in NAC regimens as 
well, in order to increase the possibility of performing breast conserving surgery 
instead of mastectomy.  
 
NAC regimens have a long duration and there is a need for methods that allow early 
discrimination between responders and non-responders. Early identification of non-
responders has several benefits: the patients can be rapidly re-assigned to new and 
potentially more effective treatment regimen. Discontinuation of ineffective 
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treatments also reduces the risk of adverse effects. Finally, rapid evaluation of 
treatments can reduce the use of expensive drugs, thereby reducing treatment costs 
for the healthcare services.  Non-invasive therapy monitoring using medical imaging 
is a potentially useful tool for early therapy monitoring in cancer. 
 
In breast cancer with distant metastasis, there is currently no available curative 
treatment. The treatment therefore aims at delaying the progression of the disease and 
to reduce symptoms with as little toxicity as possible. Chemotherapy is the treatment 
of choice, and the treatment is tailored to each patient’s hormone receptor status and 
HET-2 expression. Radiotherapy is frequently added to the regimen.   
 
1.4 Molecular subtyping of breast cancer 
A recent contribution to understanding the diversity of breast cancer is subtyping 
based on gene expression profiling. First reported in 2000, this approach has been 
used to classify breast cancer into subtypes based on expression of subsets of genes 
(Perou 2000).  Despite great molecular heterogeneity among breast cancers, clusters 
of genes (“molecular portraits”) with coherent expression patterns were found to be 
associated with specific biological features such as variation in proliferation rates and 
receptor expression. Stratification by gene expression profiling subtype was later 
demonstrated to correlate with prognosis (Sorlie 2001). Initially, five subtypes were 
defined (Figure 1). Later, a new subtype, called claudin-low, has been proposed 
(Perou 2010). 
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Figure 1 Survival analysis of breast cancer patients with different gene expression profiles. 
Patients with luminal-like breast cancer have better long-term survival than patients with ERBB2-
positive and basal-like breast cancer. Adapted from Sørlie et al (Sorlie 2001) with permission from the 
National Academy of Sciences, USA (Copyright 2001). 
  
The main distinction between the subtypes is between tumors expressing genes 
characteristic of the luminal epithelial cells, and those that are negative for these 
genes. The incidence of the gene expression subtypes varies within patient 
subpopulations depending on patient age and ethnicity (Naume 2007; Yu 2010).  The 
luminal-like subtypes constitute approximately 50-70 % of all cases, whereas the 
ErBB2+ (10 %) and basal-like (10-20%) subtypes have a lower incidence (Perou 
2010). The incidence and clinical relevance of the normal-like and claudin-low 
subtypes remains unclear. The most common subtype, termed Luminal A, typically 
exhibits strong expression of ER, and is associated with a favorable overall prognosis. 
The Luminal B subtype has low to moderate ER expression and relatively high 
expression of proliferation genes (Loi 2009).  The ErBB2+ subtype is characterized 
by amplification of the HER-2 gene and high expression of genes located adjacent to 
the HER-2 locus. The basal-like subtype has a gene expression profile similar to that 
of myoepithelial/basaloid epithelial cells, and is often associated with lack of ER/PgR 
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receptor expression and HER-2 amplification. This phenotype is often termed ‘triple 
negative’. There is considerable, but not complete, overlap between the basal-like 
gene expression profile and the triple negative phenotype (Podo 2010). Triple 
negativity is a highly sensitive, but not specific, selection criterion for basal-like 
breast cancer.  Inclusion of basaloid markers such as basal cytokeratins increases the 
specificity of immunohistochemical determination of basal-like gene expression 
profile (Rakha 2009). The claudin-low subtype is characterized by low expression of 
genes involved in cell-cell adhesion and high expression of mesenchymal cells, and is 
proposed to represent breast cancers originated from an early stage in mammary 
epithelial cell development. According to the same theory, basal-like cancers are 
proposed to represent cancers originated from epithelial progenitor cells, whereas 
luminal-like breast subtypes represent cancer originated from more differentiated 
mammary epithelium.  
 
The biology of hormone receptor negative breast cancer confirms that these represent 
a separate disease entity.  These tumors, constituting 20-40 %  of all cases, with 
higher incidence in young patients, tend to be of high grade and are frequently 
carrying mutations in TP53 and BRCA1 (Shao 2004). Patients with triple negative 
breast cancer do not benefit from any available targeted therapy. This relative lack of 
treatment options and the aggressive behavior of the tumors result in poor prognosis 
for these patients.   
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1.5 Tumor morphology 
As tumors co-evolve and communicate with their neighboring tissue, they do not 
consist of cancer cells alone. Various stromal components are also present, including 
vasculature, fibroblasts, inflammatory cells and an extracellular protein matrix. The 
cancer cells and the stromal cells interact dynamically as the tumor grows, creating a 
tumor microenvironment which ultimately promotes tumor growth and invasion. The 
cellularity of tumors is generally higher than in healthy tissue. In cases where the 
tumor microenvironment does not support cancer cell growth, for instance due to 
insufficient blood supply, necrotic areas filled with cellular debris may be formed.  
 
1.5.1 Cancer vasculature and angiogenesis 
Cancer cells can form avascular microscopic tumors, but their size is restricted to a 
diameter of 2-3 mm due to limited diffusivity of oxygen and nutrients (Folkman 
1972). To grow beyond this size, tumors need to establish a vascular supply. Through 
paracrine signalling, cancer cells recruit new blood vessels in a process called 
angiogenesis. However, the resulting tumor vasculature is both structurally and 
functionally abnormal. Typically, tumors have distorted and dilated vessels with 
abnormal interconnections and defects in the basement membrane. The structural 
abnormalities cause spatial and temporal heterogeneity in blood flow, leading to a 
microenvironment with hypoxia and acidosis. The basal membranes of tumor 
capillaries are often leaky, allowing extravasation of plasma proteins. This in turn 
causes osmotic outflow of fluid from the vasculature. Tumors often have a relative 
lack of functional lymphatic vessels, impairing the drainage of extracellular fluid. The 
interstitial fluid pressure (IFP) of tumors is therefore high compared to normal tissue. 
The high IFP reduces convective flow out of tumor capillaries, limiting the 
extravasation of small molecules such as drugs and contrast agents. 
 
1.5.2 Antiangiogenic therapy 
Sustained angiogenesis is one of the original hallmarks of cancer (Hanahan 2000). As 
tumors depend on vascularization for growth, and as they can stimulate the formation 
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of new vasculature through paracrine signalling, the concept of antiangiogenic 
therapy was conceived in the 1970s (Folkman 1971). A large body of experimental 
evidence has demonstrated that tumor progression can be arrested by inhibiting 
formation of tumor vasculature, for example through blockade of vascular endothelial 
growth factor (VEGF) (Ferrara 2005; Gerber 2005). In addition to the effect on 
neoangiogenesis, treatment with VEGF inhibitors also changes the function of 
existing tumor vasculature. These changes include reduced macromolecular 
permeability, normalization of vessel morphology and increased blood flow. This 
normalization of vasculature improves oxygenation of the tumor tissue and reduces 
interstitial fluid pressure (Jain 2005). As a result, antiangiogenic drugs may enhance 
the efficacy of chemotherapy or radiation therapy (Dickson 2007; Segers 2006).  
Figure 2 The morphology of tumor vasculature and its response to antiangiogenic therapy. 
The figure illustrates the dilated, distorted and dysfunctional vasculature of solid tumors. Following 
antiangiogenic treatment, the vascularity is decreased and the vessels have a normalized appearance. 
Reproduced with permission (Copyright 2005) from the American Association of Advances in Science 
(Jain 2005).  
The clinical role of antiangiogenic therapy remains somewhat unclear, as the survival 
benefits reported in large clinical trials have been smaller than anticipated (Hayes 
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The clinical role of antiangiogenic therapy remains somewhat unclear, as the survival 
benefits reported in large clinical trials have been smaller than anticipated (Hayes 
2011). Identification of patient subgroups most likely to benefit from the treatment is 
needed to maximize the clinical usefulness of bevacizumab. There is an unmet need 
for biomarkers that can predict response to antiangiogenic therapy, and there is also a 
need for tailor-made treatment regimens that combine chemotherapy with 
antiangiogenic drugs in a rational manner (Jain 2009).  
 
1.6 Cancer metabolism 
One of the central hallmarks of cancer is the rapid and infinite cellular proliferation. 
In order to cope with increased requirements for cellular building blocks and energy, 
the metabolism of cancer cells is remarkably different from their normal counterparts. 
The alterations in metabolism allow cancer cells to sustain a high rate of proliferation 
while at the same time protecting against oxidative damage (King 2009). In order to 
divide, cancer cells both need to replicate their DNA and to synthesize large quantities 
of cell membrane constituents and proteins. The cancer-specific metabolic phenotype 
alters metabolic flux through key metabolic pathways such as glycolysis, 
glutaminolysis and fatty acid synthesis, to meet these needs. Although the aberrant 
glucose metabolism in cancer has been known for more than 80 years, its molecular 
background is still being elucidated. Interestingly, oncogenic signalling pathways that 
regulate cell proliferation are also linked to key metabolic pathways. Thus, 
abnormalities in these pathways both trigger cell growth and provide the necessary 
metabolic conditions at the same time. As cancer cells depend on altered metabolism 
for survival and proliferation, drugs targeting metabolic pathways are being pursued 
as anticancer therapies (Tennant 2009; Tennant 2010).  
 
1.6.1 Glucose metabolism 
A frequent abnormality of cancer is the altered glucose metabolism. Under aerobic 
conditions, normal cells use glucose as a substrate in oxidative phosphorylation to 
generate energy. Under anaerobic conditions, glucose is instead fermented to yield 
lactate, a process that generates 18-fold less energy in terms of ATP yield per invested 
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glucose molecule. In contrast, cancer cells convert  glucose to lactate also under 
aerobic conditions, a phenomenon termed “the Warburg effect” (Warburg 1924). The 
reduced efficacy in energy production is compensated for through increased glucose 
uptake and glycolytic flux (Vander Heiden 2009). Increased aerobic lactate 
production is beneficial for cancer cells as it facilitates survival under hypoxic 
conditions, and as it generates energy without wasting carbon that is needed for 
synthesis of macromolecules. It has been proposed that the Warburg effect is an 
adaption to transient hypoxic conditions, providing the cancer cells with a 
biochemical tool for generating energy in the absence of sufficient oxygen to perform 
oxidative phosphorylation. However, it is also shown that leukemic cells, which are 
freely circulating and do not experience hypoxia, have abnormal glucose metabolism 
(Gottschalk 2004; Vander Heiden 2009). This is due to the specific effect of 
oncogenic mutations on the regulation of glycolytic enzymes. In most solid tumors, 
both direct oncogenic regulation and microenvironmental parameters dictate the 
glucose metabolism. The increased glycolytic flux and lactate production is exploited 
in characterization of cancer, both for diagnostic purposes and in therapy monitoring 
(Glunde 2010).  
1.6.2 Choline metabolism 
Phospatidylcholine (PtdCho) is an essential phospholipid and a major membrane 
constituent of mammalian cells. The rapid growth and proliferation of cancer cells 
require continuous rearrangement of cell membranes, and abnormalities in the 
synthesis and degradation of PtdCho is a typical biochemical alteration observed in 
cancer (Glunde 2006).  
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Figure 3 Choline metabolism 
Biosynthetic (solid lines) and catabolic (dashed lines) enzymatic reactions in phosphatidylcholine 
metabolism. In cancer, the levels of choline, phosphocholine and glycerophosphocoline are often 
increased. Reproduced with permission (Copyright 2004) from American Association of Cancer 
Research  (Glunde 2004). 
 
Cancer cells frequently have increased concentration of choline-containing 
compounds (CCCs), including choline (Cho) and phosphocholine (PCho), which are 
precursors in the synthesis of PtdCho. The levels of these metabolites may decrease 
following successful treatment of tumors (Gillies 2005). CCCs are therefore useful 
biomarkers in diagnosis and management of cancer. The abnormalities in choline 
metabolism may be related to increased turnover of cell membranes during cancer cell 
proliferation, but it has also been suggested that oncogenic signaling pathways are 
directly linked to the PtdCho metabolism (Al-Saffar 2010; Beloueche-Babari 2006; 
Yalcin 2010). Drugs inhibiting phosphocholine synthesis have been shown to have 
antitumor activity (Lacal 2001). 
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1.7 Animal models of breast cancer 
Several features of breast cancer can be studied using cancer cell cultures, including 
cell signalling, gene expression, metabolism and the effect of anticancer drugs. 
However, the heterogeneity of solid tumors, the impact of microenvironmental factors 
and interactions between cancer cells and stromal components are highly relevant 
parameters in cancer research. Through use of animal models of breast cancer, the 
interactions between cancer cells and their surroundings and the association between 
microenvironment and cancer cell phenotype can be studied. Breast cancer is a 
heterogeneous disease, and a variety of animal models have been established. In the 
context of multistage initiation and progression of breast cancer, these models have 
different strengths and limitations. No single animal model can mimic all aspects of 
the disease. Instead, optimal choice of model depends on the objective of the research. 
Breast cancer animal models are traditionally based on cultured human cancer cell 
lines (Lacroix 2004). Models based on breast cancer cell lines have provided a wealth 
of information about gene expression, signalling pathways and cancer cell 
proliferation. Established cell lines are easily cultivated, can be grown as xenografts 
in immunocompromised animals, and generally yield reproducible and quantifiable 
data. These cell lines are considered relevant to human disease as they are derived 
from human cancers. Although no single cell line is truly representative of human 
breast cancer, panels of cell lines can be used to model the heterogeneity of breast 
cancer. A limitation of such models is their monoclonal nature, as human breast 
cancers consist of a multitude of genetically distinct subpopulations of cells.  
Furthermore, only cell clones that have adapted to artificial culture conditions are 
represented. It should also be noticed that the most frequently used breast cancer cell 
lines are derived from advanced human cancers or metastatic tumors, and that they 
may not represent the most common types of breast cancer.  
 
In order to establish more relevant models of cellular breast cancer heterogeneity, 
models based on transplanted primary patient tumor tissue (PPTT) have been 
established. Such models evidently bridge the gap between the original patient tumor 
and the in vivo model. It has been shown that these models maintain many key 
features of the primary patient tumor, including morphology and the molecular 
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signature (Bergamaschi 2009; Marangoni 2007). In contrast to models based on 
cultured cell lines, the response to therapy in PPTT-based models is closely correlated 
to the response of the parent tumor (Boven 1992).  However, the transplantation 
efficiency is low, and the more aggressive breast cancer subtypes may be 
overrepresented in panels of PPTT-based xenografts (Marangoni 2007). A limitation 
of both cell line based and PPTT-based xenografts are the use of immunodeficient 
host animals, as the impact of the immune response on tumor progression is lost in 
these models. 
 
For detailed examination of oncogenic transformation and tumorigenesis, genetically 
engineered mouse models (GEMM) have also proven valuable. Although cancer 
arising from mouse cells cannot recapitulate all aspects of human breast cancer, 
GEMM allow studies of relationships between oncogenic signalling and tumor 
initiation and progression. Initially, transgenic models were used to study inherited 
cancer syndromes, but development of more sophisticated multiallelic models 
mimicking spontaneous tumorigenesis has allowed more detailed examination of 
multi-step oncogenic transformation. However, such models have been difficult to 
adapt to translational cancer research due to long timelines and difficulty in 
establishing large cohorts (Heyer 2010). One possible advantage of GEMMs is that 
they are directly applicable to preclinical development of molecularly targeted drugs. 
The main disadvantage is the fact that although mice and humans develop cancer 
through similar mechanisms, species-specific phenotypes are frequently observed. 
Despite advances in genetic engineering, the most common subtypes of breast cancer 
are difficult to recapitulate in GEMMs (Vargo-Gogola 2007).   
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1.8 Magnetic resonance in biomedicine 
The principles of nuclear magnetic resonance were discovered by Rabi, Purcell and 
Bloch in the 1940s, and have later found widespread use in modern medicine (Bloch 
1946; Purcell 1946; Rabi 1938). Initially, the interaction between nuclei with spin 
angular momentum and a magnetic field was investigated as a physical phenomenon. 
During the 1950s, the methods had developed to allow studies of biological material. 
Using increasingly sophisticated methods, nuclear magnetic resonance has become a 
fundamental factor in modern medicine and biomedical research. Not only 
anatomical, but also functional and biochemical properties of biological specimens 
can be assessed due to the inherent versatility of the technique.  
 
1.8.1 Principles of nuclear magnetic resonance 
In a strong magnetic field, nuclei in possession of a spin angular momentum will align 
either with or against the magnetic field. The energy levels of these two orientations 
are slightly different, and at equilibrium the nuclei will have a magnetic moment 
proportional to the strength of the magnetic field and spin properties of the nuclei. 
The magnetic moment of the nuclei precess around the axis of the magnetic field with  
a frequency (Ȧ0) proportional to their gyromagnetic ratio (Ȗ) and the magnetic field 
strength (B0) according to equation (1), and this frequency is called the Larmor 
frequency. 
 
Ȧ0 = Ȗ B0         (1) 
 
This aligned equilibrium can be perturbed by employing an additional magnetic field 
perpendicular to the static magnetic field (typically through a radiofrequent (RF) 
electromagnetic pulse). If the additional magnetic field oscillates with the same 
frequency as the Larmor frequency, the nuclei will be exited and their magnetic 
moment will change direction according to the properties of the RF pulse, while 
retaining its rate of oscillation. This phenomenon represents the “resonance” property 
of magnetic resonance spectroscopy and imaging. Following the excitation pulse, the 
magnetization will return to equilibrium through a process called relaxation. During 
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relaxation, the net magnetic moment gradually returns to its position aligned with the 
static magnetic field, and this process induces an electric current in a receiving 
electric coil. This electric current is the signal received in magnetic resonance 
experiments, and the amplitude, duration and shape of the signal depends on the 
properties of the exited sample. By mathematically resolving the signal, information 
about the composition of the sample can be extracted. 
1.8.2 Magnetic resonance spectroscopy (MRS) 
Due to minuscule field inhomogeneities caused by the local chemical environment, 
the resonance frequency is not identical for all the nuclei. Importantly, shielding 
electrons in the environment reduce the magnetic field experienced by the nuclei, 
thereby reducing the resonance frequency. Nuclei located in various positions in 
biomolecules resonate at different frequencies, providing information on the chemical 
content of a sample. This phenomenon is known as chemical shift. Closely located 
nuclei also influence each other through spin couplings, resulting in the splitting of a 
signal into multiple peaks, in characteristic patterns depending on the nature of the 
coupling interactions. These patterns provide highly specific structural information. 
The combined effects of chemical shift and coupling constants allow identification of 
different chemical entities in biological specimens using magnetic resonance 
spectroscopy (MRS). As signal strength is proportional to the number of protons that 
were excited by the RF pulse, quantification of metabolites in the spectra may be 
possible provided that a suitable internal or external calibration standard is used. In 
biomedicine, the most commonly studied nucleus is 1H, due to its high natural 
abundance in biological specimens and its inherent high magnetic resonance 
sensitivity. A wide range of biomolecules can be detected using 1H MRS. However, 
other nuclei such as 13C, 15N, 19F and 31P may also be utilized for special applications.  
The use of such heteronuclei depends on the same physical phenomena, but requires 
customized experimental protocols that are adapted to the inherent magnetic 
resonance sensitivity and Larmor frequency of the nuclei.  
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Ex vivo magnetic resonance spectroscopy
In order to improve the spectral resolution in MRS of biological tissues, biopsies may 
be sampled and analyzed in high-field spectrometers. The better sensitivity, higher 
field strength and improved field homogeneity is improved compared to in vivo MRS.
However, anisotropic interactions are still present. By spinning the sample at an angle 
of 54.7q (the magic angle) to the static magnetic field, these interactions are averaged 
out, producing signal lines comparable to those achieved in in vitro MRS of solutions. 
This method has been termed high resolution magic angle spinning MRS (HR MAS 
MRS) and is a useful tool for analysis of intact tissue specimens. The method has 
been widely applied in studies of cancer metabolism, as information on a large 
number of metabolites can be obtained. In addition, the simple sample preparation and 
the availability of the sample for subsequent analyses are advantages of HR MAS 
MRS (Moestue 2011b).
Figure 4 Schematic presentation of Magic Angle Spinning.  
The rotor is oriented at an angle (E) of 54.7q to the static magnetic field (B0). The rotor spins around its 
own axis with a spin rate of Zr. Reproduced with permission from Beathe Sitter, MR Cancer Group, 
NTNU.  
In vivo magnetic resonance spectroscopy 
In magnetic resonance spectroscopy of homogenous biological specimens such as cell 
extracts or intact cultured cells, information on the localization of the different 
metabolites is not needed. However, when MRS is performed in living subjects, it is 
frequently of interest to obtain metabolic information from a distinct organ or other 
tissue of interest, such as a solid tumor. Localized excitation of nuclei is therefore the 
most frequently used approach in in vivo MRS. This can be achieved using the 
principles of magnetic resonance imaging, where spatial information is added to the 
data through use of magnetic field gradients. By applying gradients to the static 
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magnetic field, the Larmor frequency becomes a function of localization in the field. 
This allows localized excitation of nuclei through specialized, spatially selective pulse 
sequences such as the PRESS sequence (a 90q RF pulse followed by two 180q RF 
pulses, all along perpendicular axes). The localization techniques can be used to 
delineate one well-defined voxel (single-voxel MRS) within the tissue of interest. 
Alternatively, multiple voxels can be defined in single or multiple slices. This allow 
spectroscopic mapping of the tissue of interest, and is referred to as MR spectroscopic 
imaging (MRSI) or chemical shift imaging (CSI). 
In order achieve a high spectral resolution in in vivo MRS, it is important with a 
highly homogenous static magnetic field. High field strength also improves the 
separation of metabolites, as the difference in resonance frequency is proportional to 
field strength. Still, the spectral resolution in vivo typically allows identification of a 
limited number of metabolites. 
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Figure 5 Spectral resolution in in vivo and ex vivo MR spectroscopy 
Following the acquisition of an anatomic MR image (middle), a localized volume of interest for 
spectroscopic assessment can be defined within the tumor (represented by the yellow voxel). The in 
vivo MR spectre (top) represents the signal obtained from this voxel. Harvesting a biopsy (represented 
by the yellow cylinder) from this tumor allows acquisition of an ex vivo spectrum at higher field 
strength (bottom). Image and spectra were obtained in a xenograft model of luminal-like breast cancer 
(MAS98.06). The in vivo spectrum was obtained in a 7T small animal scanner (PRESS sequence, voxel 
size: 3 x 3 x 3 mm, scan time: ca 6 min). The ex vivo spectrum was obtained from a 15-mg biopsy from 
the same tumor, analyzed using HR MAS MRS on a 14.1T spectrometer (CPMG sequence, scan time: 
ca 6 min).  Some typical metabolites are identified in both spectra. Reproduced with permission from 
Moestue et al Mol Oncol 2011; 5 (3); 224-241.  
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Analysis of MRS data
In order to use MRS data, the signal at different resonance frequencies has to be 
assigned to the correct biomolecules. Analyses of reference standards in solutions can 
be used to generate a library of spectra representing candidate molecules. Careful 
matching of reference spectra with spectra from biological samples is used to identify 
the peaks. In some cases, multidimensional spectroscopy is needed to confirm the 
identity of metabolites which resonate with similar frequency.  
 
The MRS signal is proportional with the metabolite concentration (taking the number 
of protons in each metabolite into account). Therefore, the metabolite concentrations 
can be quantified. The first step in this process is determination of the area under each 
metabolite peak. Due to variation in peak width between spectra, the peak area is a 
more accurate measure of metabolite concentration than the peak height. This can be 
done using polynomial regression or other approaches that translate the peaks of the 
spectre into a mathematical function.  
 
Analyzing the ratios between different peak areas can provide valuable information. 
In in vivo MRS, this is the most commonly used method for analyzing the spectra. For 
absolute quantification of metabolite concentration it is more common to use a 
reference with known concentration. A commonly used approach is to determine the 
area of the water peak in the spectre and then experimentally determine the water 
content of the tissue. Assuming that the water content in tissue is constant, this 
method has been applied to in vivo MRS. Ex vivo and in vitro, an external reference 
standard can be added to the sample in known concentration before analysis. 
Recently, a method for introducing an electronic reference signal into the spectra has 
been introduced (ERETIC) (Barantin 1997).  Calibrating this reference signal to 
reference standards allow direct quantification of metabolite concentrations.  Finally, 
if the stability of the spectrometer is high enough, the peaks in the spectra can be 
assumed to be directly proportional to the metabolite concentration as long as the 
acquisition parameters remain constant. Thus, the areas can be directly calculated 
based on a calibration standard curve obtained from a reference standard solution 
(Pulcon) (Wider 2006). 
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1.8.3 Magnetic resonance imaging (MRI) 
As magnetic resonance signal strength depends on the composition of a biological 
specimen, reconstruction of magnetic resonance data into images representing 
anatomy is a widely used modality in medical imaging. Magnetic resonance imaging 
(MRI) requires the use of magnetic field gradients in at least three directions (often 
termed the x-, y- and z-axis, where the z-axis is parallel to the static magnetic field 
B0), allowing spatial encoding of the emitted signal. By superimposing a field 
gradient parallel to the static magnetic field B0, the resonance frequency of the 
protons becomes a function of their position along the field. This allows selective 
excitation of a tissue slice, defined by the frequency of the RF-pulse. Application of a 
phase encoding gradient and a readout gradient along the x- and y- axis give the 
relaxing protons a phase shift depending on their location along the x-axis and a 
frequency depending on their location along the y-axis. The detected signal is 
complex and can be expressed as a function of spatial frequencies in the x,y-plane. 
The longitudinal magnetization in each position of the exited slice can be calculated 
through Fourier transformation, allowing reconstruction of an image.  
 
By taking the magnetic properties of protons into account in the excitation sequence, 
images with different type of contrast can be acquired. Both the proton density, the 
longitudinal relaxation rate (T1) and the transversal relaxation rate (T2) are tissue-
dependent parameters. In T1 and T2-weighted images, the contrast represents 
differences in T1 and T2 in the imaged tissue, respectively. T1 and T2 can be 
modulated using contrast agents, further increasing the ability of MRI to differ 
between various tissues. Some contrast agents, including gadolinium complexes, 
cause concentration-dependent reduction of T1. This leads to higher signal intensity in 
tissue with high concentration of contrast agent. Other contrast agents, such as iron 
oxide particles, cause concentration-dependent reduction in T2 and lower signal 
intensity in tissues with high concentration of contrast agent. In both cases, 
differences in contrast agent concentration between tissues increase the contrast in 
MR images.  
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Besides anatomical imaging, MRI can also be used to visualize functional properties 
of tissue. In cancer, diffusion-weighted MRI (DW-MRI) and dynamic contrast-
enhanced MRI (DCE-MRI) are the most frequently used techniques.  
DW-MRI
Diffusion-weighted MR imaging is a technique that allows measurement of random 
thermal movement of water molecules (diffusion). As diffusion depends on the 
amount of macromolecular barriers (cell membranes, stromal macromolecules), DW-
MRI provides information on the cellular density of tissues. This information is 
relevant in medical imaging, as the water diffusivity in pathologic tissue may differ 
from normal tissue. Tissue with high cellular density (and therefore low water 
diffusivity) is frequently observed in solid tumors. Response to treatment may cause 
changes in diffusivity, allowing the use of DW-MRI both in diagnosis and treatment 
monitoring of cancer (Padhani 2009; Padhani 2011). As the signal in MRI depends on 
the location of protons, carefully designed pulse sequences can be used to indirectly 
measure the diffusivity of water. These sequences utilize a pair of bipolar gradients, 
often termed Stejskal-Tanner gradients, which sensitizes the signal to net 
displacement of water molecules during the imaging sequence (Stejskal 1965).  The 
gradients are applied before and after the 180q pulse in a spin-echo sequence. Protons 
that move in the interval between these gradients will gain a net phase shift, causing a 
loss of signal. The signal loss depends on the strength and duration of the diffusion 
gradients, and the time interval between the gradients. The accumulative effect of 
these parameters is reflected in the b-value. The relationship between the b-value and 
the signal intensity (SI) is defined as: 
 
ADCb
0 eSISI
          (2) 
 
where SI0 is the signal intensity without application of diffusion gradients and ADC is 
the apparent water diffusivity. By performing experiments with variable b-values, the 
ADC can be calculated through exponential curve fitting of the resulting signal 
intensities. The diffusion gradients are usually applied in three orthogonal directions, 
to average out potential anisotropy. In tissues where water molecules diffuse freely, 
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the movement causes a signal loss and the tissue appears with low signal intensity in 
the diffusion-weighted images. Conversely, densely packed tissue has low ADC and 
appears with high signal intensity.  
DCE-MRI
In dynamic contrast enhanced MRI a series of images with identical geometrical 
orientation is acquired before and after intravenous injection of a contrast agent. 
Following injection, the distribution of contrast agent depends on tissue perfusion and 
the rate and extent of contrast agent extravasation. Contrast agents in clinical use are 
often based on paramagnetic elements such as gadolinium or manganese. Gadolinium 
shortens T1 relaxation time and increases signal intensity in T1-weighted MR images, 
but gadolinium ions are highly toxic. When complexed or bound to a carrier 
molecule, the magnetic properties are retained whereas toxicity is minimized. Most 
commercial gadolinium-containing contrast agents have similar pharmacokinetics, 
with rapid distribution to extracellular (but not intracellular) fluid and renal excretion 
of the contrast agent. Several different imaging sequences can be used in DCE-MRI, 
all with different advantages and disadvantages. The spin-echo sequence is time-
consuming but has the advantage of a linear contrast agent concentration/signal 
intensity relationship (Larsson 1990). The signal intensity (SI) for a spin-echo 
sequence follows equation (3): 
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where U is the proton density, TR the repetition time, TE the echo time, and T1/T2 are 
the longitudinal and transverse relaxation times, respectively. By choosing a short 
echo time, the sequence will be T1-weighted and the signal intensity will be strongly 
dependent on contrast agent concentration. The T1 relaxation rate is related to the 
contrast agent concentration (C) and relaxivity (r1), according to equation (4): 
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where T10 is the longitudinal relaxation time in the absence of contrast agent. The 
pre-contrast longitudinal relaxation time therefore has to be measured prior to the 
DCE-MRI acquisition, for example by varying the repetition time in a spin-echo 
sequence.  
 
The change in contrast agent concentration over time is reflected in the series of MR 
images. This allows analysis of temporal and spatial components of contrast agent 
distribution between tissue compartments. In solid tumors, blood vessels are typically 
leaky, allowing rapid extravasation compared to surrounding tissue. In breast cancer, 
it was early demonstrated that DCE-MRI can differentiate between benign and 
malignant lesions, and that tumor size measured using DCE-RMI correlates well to 
pathologic tumor size (Gribbestad 1992). The use of DCE-MRI in breast cancer 
management has later expanded to include staging, screening of patients at high risk, 
monitoring of treatment response, and follow-up after surgery and radiotherapy 
(Turnbull 2009).  
Analysis of DCE-MRI data
Signal intensity/time curves obtained from DCE-MRI acquisitions can be evaluated 
both empirically and numerically. Empirical methods are simple and robust, whereas 
numerical methods often can provide additional functional information. Due to their 
simplicity, empirical methods are frequently used in the clinic. Parameters derived 
from signal intensity/time curves include area under the signal intensity curve (AUC), 
relative signal intensity (RSI) and time to peak concentration (TTP). 
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Figure 6 Empirical analysis of signal enhancement curves 
Signal enhancement curves from DCE-MRI consist of several phases (A). The area under the curve 
(AUC) is illustrated in (B). Partial AUCs can also be calculated. In (C), the signal increase relative to 
baseline (RSI) is illustrated. It can also be calculated at a fixed time point. Time to peak (TTP) is the 
time to reach the intensity maximum from the time point of injection (D).  
  
High AUC and RSI values combined with short TTP indicate rapid and extensive 
extravasation of contrast agent, suggestive of malignant disease. In addition, the curve 
shape in each voxel can provide information on the aggressiveness of the tumor. A 
rapid increase and decline in contrast agent concentration is frequently associated 
with aggressive disease, whereas slow and persistent increase is a typical feature of 
necrosis and benign breast lesions.  
 
Through pharmacokinetic modelling of the contrast agent concentration, the vascular 
function of tumors can be quantitatively evaluated. By fitting a mathematical model to 
the signal intensity/time curve, the rate and extent of contrast agent transport from the 
blood and into the extravascular extracellular space (EES) can be estimated. 
Gadolinium complexes are extracellular tracers, and the contrast agent is therefore 
restricted to the plasma volume and the EES. Immediately following injection, it is 
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assumed that the contrast agent is evenly distributed throughout the entire plasma 
volume. Then, it is rapidly distributed into the EES, reaching a distributional 
equilibrium. Finally, a slower decline in plasma contrast agent concentration due to 
renal excretion is observed. The association between arterial and tissue concentration 
of contrast agent over time is shown in Figure 7.  
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Figure 7 Arterial and tissue contrast agent concentrations.  
It is assumed that the contrast agent mixes into the entire plasma volume immediately after injection. 
The contrast agent then distributes into tissue at a rate determined by blood flow and extraction 
fraction. Later, the contrast agent is renally eliminated from the blood, which is reflected in declining 
tissue contrast agent concentration. 
 
The rate of contrast agent transfer (Ktrans) between the plasma volume and the EES 
depends on the concentration difference between these two compartments, the blood 
flow and the permeability surface product of the vascular bed, and is described by 
equation (5): 
 
)1( HctFEK trans  U        (5) 
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where E is the extraction fraction, F is blood flow, U is tissue density and Hct is the 
hematocrit. The two-compartment pharmacokinetic model for contrast agent 
concentration also requires knowledge about the amount of contrast agent that is 
supplied to the tissue of interest, also known as the arterial input function (AIF). The 
plasma concentration of extracellular contrast agents over time is typically described 
by a biexponential function: 
 
)()( btatp eBeADtC
       (6) 
 
where D is the contrast agent dose, A and B are the amplitudes of each exponential 
component, and a and b are their respective rate constants. For accurate estimation of 
contrast agent pharmacokinetics, the AIF should ideally be measured in an artery 
supplying the tumor in each individual subject during DCE-MRI acquisition. 
However, this is not always achievable, and an AIF representative for the entire study 
population is often used instead.  The total tissue concentration of contrast agent (Ct) 
can be expressed as a function of time (t) (6): 
 
    ³  t vttKptransppt dtetcKtCvtC etrans
0
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where vp is the volume fraction of blood plasma, Cp is the concentration of contrast 
agent in the blood plasma, Ktrans is the volume transfer constant between plasma and 
EES and ve is the volume fraction of EES (Tofts 1999). Taking the AIF into account, 
this model allows calculation of contrast agent concentration in the vascular space and 
the EES, as well as the rate of transfer between the two compartments. 
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1.9  MR in breast cancer  
As MRI and MRS can provide both anatomical and functional information, these 
techniques are useful tools both in basal breast cancer research and for clinical breast 
cancer management. Morphology, vascular function and cellular density of breast 
tumors can be evaluated using MRI, whereas MRS has been widely used for 
assessment of breast cancer metabolism. In the following section, the clinical role of 
MRI and MRS in breast cancer is discussed, as well as the most common applications 
of MRI and MRS in preclinical cancer research. 
1.9.1 Current clinical status of MR in breast cancer 
The use of MRI in breast examinations is rapidly increasing, despite a lack of clear 
evidence of its value in preventing breast cancer deaths. MRI using low-molecular 
Gd-based contrast agents is currently the most used method in breast MR 
examinations. This is a sensitive, but only moderately specific method. However, the 
performance of MRI in various clinical settings has been thoroughly examined, and 
its current clinical use in screening of high-risk populations and in preoperative 
treatment planning is therefore justified. Future use of MRI and MRS in breast cancer 
management is likely to include a combination of several different methods in each 
patient examination. This allows both morphological and functional assessment of the 
pathology, which in general has been shown to increase sensitivity and specificity of 
the examination (Sardanelli 2011). 
1.9.2 MRI in breast cancer 
Diagnosis and staging
Contrast-enhanced MRI is a more sensitive method for detection of breast tumors, 
including DCIS and multifocal tumors, than X-ray mammography (XRM) (Sardanelli 
2010; Schnall 2005). Based on this, MRI is used for staging and treatment planning of 
newly diagnosed breast cancer. Overall, MRI has been reported to have a positive 
impact on the choice of surgical procedure in approximately 10% of cases (Sardanelli 
2010). Population-wide screening for breast cancer is currently performed using 
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XRM, and MRI is not considered to be cost-effective enough to be used for this 
purpose. However, in high-risk populations, MRI is increasingly used in screening for 
lesions. MRI has high diagnostic sensitivity compared to other imaging modalities, 
and it is recommended that carriers of BRCA1/BRCA2 mutations or first-degree 
relatives of carriers should undergo annual MRI screening  (Mann 2008; Norsk bryst 
cancer gruppe (NBCG) 2011). Contrast-enhanced MRI has also been suggested for 
evaluation of response to neoadjuvant therapy (NAC). In this setting, the aim is to 
downstage the tumor from inoperable to operable, or from a size that dictates radical 
mastectomy to a size that allows breast-conserving surgery. MRI is useful in surgery 
planning following completion of NAC, but may also be considered for early 
prediction of response to NAC and prediction of survival. Response monitoring in 
NAC may be an important application for MRI, as 10 - 20% of patients (depending on 
treatment regimen and response criteria) are classified as non-responders (Buchholz 
2003). Rapid monitoring of treatment effect would allow discontinuation or change of 
treatment regimen or re-planning of surgical treatment. MRI is a more accurate tool 
for monitoring effect of NAC than XRM or ultrasound, and provides a better basis for 
surgical planning than these modalities (McLaughlin 2011a). The utility of MRI in 
early assessment of response to NAC and on long-term outcome needs to be further 
investigated, as the heterogeneity of breast cancer and the variety of drugs used in 
NAC regimens are not yet fully accounted for (Sardanelli 2010). As an example, it 
has been reported that MRI following bevacizumab-containing NAC in HER-2 
negative breast cancer causes underestimation of the residual tumor mass (Chen 
2008).  
DW-MRI
The majority of MRI examinations are performed using contrast-enhanced T1-
weighted imaging. However, several studies have demonstrated that DW-MRI also 
can detect malignant breast cancer lesions. More interestingly, addition of DW-MRI 
to the imaging protocol has been demonstrated to increase the diagnostic value of 
breast MRI (Ei Khouli 2010; Kul 2011; Partridge 2009).  As benign lesions in general 
have higher ADC values than malignant lesions, DW-MRI tends to increase the 
specificity of breast MRI examinations. It has also been demonstrated that 
morphological changes after NAC are preceded by increased ADC values (Ei Khouli 
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2010; Pickles 2006). This suggests that ADC may have potential role as an early 
marker for response to NAC. It has also been reported that pre-treatment ADC values 
may have predictive value (Park 2010). In animal xenograft models of breast cancer, 
DW-MRI has been used to demonstrate efficacy not only of classical 
chemotherapeutics, but also by molecularly targeted drugs (Aliu 2009; Kim 2008).  
DCE-MRI
As breast cancer MRI examinations generally depend on Gd-chelate based contrast 
agents for tumor delineation, a DCE-MRI protocol can be included with relative ease. 
However, care must be taken to balance the need for both high temporal resolution 
and high spatial resolution. The choice of protocol dictates how the data should be 
analyzed. In order to perform pharmacokinetic modelling of the contrast 
enhancement, high temporal resolution is generally needed. Semiquantitative methods 
are less dependent on temporal resolution, and can contribute positively to increased 
sensitivity and specificity in lesion detection and differentiation.  The trade-off 
between spatial and temporal resolution has been studied by Kuhl et al by direct 
comparison of two different DCE-MRI protocols in the same patient cohort (Kuhl 
2005). This study demonstrated that a low temporal resolution caused loss of 
diagnostically relevant information. However, the protocol with high spatial 
resolution had a significantly better diagnostic performance, suggesting that that 
delineation of tumor margins and visualization of internal tumor architecture was 
important factors for the readers of the images. It has also been suggested that DCE-
MRI increases the performance of staging examinations due to its ability to detect 
small lesions and intraductal spread (Hata 2004). However, despite the number of 
studies demonstrating that DCE-MRI increases diagnostic accuracy in small patient 
populations, a multicentre trial including 1623 women with newly diagnosed breast 
cancer demonstrated that inclusion of DCE-MRI to the diagnostic regimen did not 
have a measurable impact on the number of re-operations needed (Turnbull 2010). 
This suggests that DCE-MRI should be used as an additional examination in carefully 
selected cases rather than as a standard method for staging of tumors.  
DCE-MRI may also be used in assessment of response to NAC. In addition to 
tracking anatomical and morphological changes, functional indicators for early 
response monitoring have been evaluated in clinical trials. The response may be 
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predicted based on the pre-treatment MRI examination, or based on changes between 
pre-treatment and early post-treatment MRI examinations (Heldahl 2010; Pickles 
2005; Pickles 2009). 
Breast cancer with rapid wash-out of contrast agent in the pre-treatment MRI 
examination is associated with positive response to NAC (Heldahl 2010). It has also 
been found that breast tumors with high levels of perfusion and vessel permeability 
before NAC are associated with shorter overall survival (Pickles 2009).  Reduction of 
tumor volume determined by early post-treatment DCE-MRI has been found to 
predict response to NAC (Heldahl 2010; Padhani 2006). Semi-quantitative analysis of 
contrast agent pharmacokinetics has also been investigated, and a reduction in mean 
RSI has been described in responders (Johansen 2009). Several studies using 
compartmental modeling of DCE-MRI data have demonstrated that decrease in Ktrans 
and the amplitude of signal enhancement is associated with a favorable response to 
therapy (Pickles 2005; Turnbull 2009).  The optimal time-point for performing 
follow-up DCE-MRI is still debated (McLaughlin 2011b).    
Antiangiogenic treatment
As DCE-MRI measures vascular function, there has been particular interest in 
assessment of response to antiangiogenic therapy. A reduction in neoangiogenesis 
caused by bevacizumab or other antiangiogenic agents should produce fewer and less 
leaky tumor blood vessels, which would be reflected in the contrast enhancement 
pattern observed by DCE-MRI. Two different studies have demonstrated reduced 
Ktrans or AUC1min after bevacizumab therapy, an effect that has been shown to be 
additive to concomitant administration of docetaxel (Baar 2009; Wedam 2006). The 
reduction in contrast enhancement mostly occurred during the first cycles of NAC, 
and was not correlated to clinical or pathological response.  
1.9.3  MRS in breast cancer 
Abnormal choline metabolism is found in breast cancer as well as in several other 
cancers, and MRS can be used to detect the presence of the choline-containing 
compounds glycerophosphocholine (GPC), phosphocholine (PCho) and choline. In 
clinical MRS examinations, the signal from these metabolites overlap considerably 
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and the readout parameter is therefore their cumulated signal at 3.2 ppm, denoted total 
choline (tCho). In healthy breast cancer tissue, a tCho peak is normally not found. In 
benign lesions, tCho is also absent or very low. A high tCho peak is therefore 
associated with malignant disease (Gillies 2005).  A meta-analysis of five studies, 
including 100 malignant and 53 benign lesions demonstrated a sensitivity of 83% with 
a specificity of 85%, suggesting the possible utility of MRS as a diagnostic tool 
(Katz-Brull 2002a). However, MRS performance is associated with tumor size, and 
for small lesions the sensitivity of the method is significantly decreased (Tozaki 
2009). This is considered to be related to the sensitivity of MRS at 1.5 T rather than 
an intrinsic metabolic property of small tumors (Katz-Brull 2002a). The low 
sensitivity is also thought to be a problem for reliable use of MRS in monitoring 
response to NAC (Haddadin 2009). Accurate therapy monitoring is also complicated 
due to the complex changes that are observed in individual choline-containing 
metabolites, which depend on both the tumor type and the treatment (Beloueche-
Babari 2010b). Technical improvements, including MRS at 3 T or MRSI 
examinations may increase specificity, but the role of MRS in breast cancer 
examinations remains unresolved (Jagannathan 2009). 
1.9.4 MRI in preclinical cancer research 
The applications for MRI and MRS in cancer are continuously being extended and 
improved through the use of animal models. In particular, MR is used in order to 
understand the biology of tumors and to describe various biological characteristics. 
Using parametric maps, microenvironmental features such as necrosis, hypoxia and 
intratumoral fluid pressure can be mapped using MRI (Bhujwalla 2002; Egeland 
2009; Gulliksrud 2009). Knowing how these microenvironmental parameters differ 
between various cancer subtypes, it has been suggested that MRI holds the potential 
to discriminate between different cancer subtypes or to predict tumor aggressiveness 
(Bhujwalla 2001; Wu 2009). One of the fields that have received most attention is 
how DCE-MRI can be used to monitor changes in vascular function following various 
interventions. Performing DCE-MRI in animal models may be technically challenging 
due to motion artefacts and small lesions, but on the other hand it offers advantages in 
terms of reproducibility and flexibility and the possibility to use contrast agents that 
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are not clinically available. The vascularization of xenografted tumors may in some 
aspects differ from that of human tumors, but the responses to therapy observed in 
animal models may still be clinically relevant.  
 
The effect of chemotherapy and radiotherapy in xenograft models can be monitored 
using DCE-MRI, supporting the use of this technique in monitoring response to 
therapy (Jensen 2010; Rofstad 2009). Efforts have also been made to co-register 
DCE-MRI data with histological data or functional in vivo measurements in order to 
understand how tumor biology is reflected by the DCE-MRI parameters (Ellingsen 
2009; Ellingsen 2010; Gulliksrud 2011). In the last decade, DCE-MRI has been used 
for monitoring response to antiangiogenic drugs, thereby contributing to increased 
understanding of the effects of these drugs.  The importance of angiogenesis in cancer 
was first suggested in the 1970’s (Folkman 1971). It took nearly 20 years before the 
angiogenic growth factor VEGF was described, but this lead to an explosive interest 
in this as a druggable anticancer target (Leung 1989). This has culminated in the 
development of several clinical angiogenesis inhibitors such as the specific anti-
VEGF antibody bevacizumab and receptor tyrosine kinase inhibitors such as sorafenib 
and sunitinib (Levitzki 2010). Bevacizumab as well as numerous new drug candidates 
either inhibiting angiogenesis or causing disruption of newly formed blood vessels 
(vascular disrupting agents) have been evaluated in animal models of cancer. Through 
the use of macromolecular contrast agents, microvascular leakiness and fractional 
plasma volume are readily assessed. Such contrast agents are too large to leak out of 
normal capillaries, but can cross the endothelial lining of immature tumor blood 
vessels. Following antiangiogenic therapy, the transfer of macromolecular contrast 
agents from the vasculature to the interstitial space is greatly reduced. Although these 
contrast agents are not approved for clinical use, they are useful tools in evaluating 
the biological activity of potential antivascular drug candidates (Padhani 2003). Using 
this approach, the effect of bevacizumab has been studied in several different cancer 
models (Preda 2004; Turetschek 2004). In addition, drugs targeting other molecular 
pathways may also indirectly inhibit angiogenesis. As an example, drugs inhibiting 
the PI3K/Akt/mTOR axis have been shown to both reduce proliferation of cancer 
cells and to reduce neoangiogenesis, possibly due to inhibition of downstream targets 
such as HIF-1 (Lane 2009; Schnell 2008; Schwartz 2010). The effect of vascular 
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disruption agents such as combretastatin A4 phosphate can also be monitored using 
DCE-MRI. These agents typically cause a rapid (within a few hours) decline in Ktrans 
due to a decrease in the number of functional blood vessels and reduced blood flow 
(Galbraith 2003). 
1.9.5 MRS in preclinical cancer research 
Breast cancer typically exhibits most characteristics of a cancer-specific metabolic 
phenotype, with abnormal glucose metabolism and elevated levels of CCCs. 
Therefore, the metabolism of breast cancer has been extensively studied using both in 
vitro, ex vivo and in vivo. This is in part due to the potential use of metabolites as 
prognostic or predictive biomarkers, or in assessment of response to therapy. Another 
reason for the interest in the abnormal metabolism is the direct link between 
oncogenic signalling and regulation of metabolic pathways, suggesting that metabolic 
pathways may contain potential new drug targets.  
 
Initial studies in animal models used 31P MRS to demonstrate the differences between 
tumors and normal tissue with respect to phosphorous-containing metabolites 
(Griffiths 1982). These experiments suggested that MRS indirectly can describe the 
microenvironment of tumors. By determining the chemical shift of inorganic 
phosphorous, the tumor pH can be determined. The presence of high phosphomono- 
and -diesters was also noticed. Through 1H MRS of cultured breast cancer cells it has 
been shown that malignant transformation is strongly associated with high 
concentrations of phosphocholine (PCho) (Eliyahu 2007b; Glunde 2004). The 
metabolic flux in the choline pathway has also been studied in vitro using 13C-
enriched choline as a tracer, demonstrating that choline uptake and conversion of 
choline into PCho is upregulated in breast cancer. Conversion of PCho to PtdCho is 
not upregulated, suggesting that the abnormal choline metabolism does not contribute 
to increased synthesis of cell membrane constituents (Katz-Brull 2002b). In fact, 
PtdCho catabolism by phospholipase C contributes to increased PCho concentration 
in breast cancer cells but not in immortalized human mammary epithelial cells. 
However, substantial GPC contributions to the tCho signal have been observed both 
in xenograft models and in human biopsies analyzed ex vivo, suggesting that 
microenvironmental or genetic/epigenetic factors are likely to be important factors in 
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determining the choline metabolite pattern (Moestue 2010; Sitter 2006). This is also 
illustrated by discrepancies between studies using the same breast cancer cell lines, 
suggesting that experimental conditions may have a large impact on the choline 
metabolism in vitro. The abnormal choline metabolism has traditionally been linked 
directly to the increased proliferation rate of cancer cells (Podo 1999). However, 
recent studies have also suggested a close relationship between oncogenic signalling 
pathways and the regulation of the PtdCho cycle, suggesting that choline metabolites 
under given conditions may function as oncometabolites (Yalcin 2010).  
 
Although the regulation of choline metabolism in vivo is not completely understood, 
tCho has been suggested a clinically relevant biomarker for response to treatment both 
with anticancer drugs and radiotherapy. This is predominantly thought to be caused 
by a reduction of PCho concentrations following successful treatment. Studies of 
animal models and cultured cancer cells have suggested that choline metabolite 
responses to therapy are complex. First, the contribution of GPC to the tCho signal 
should be taken into account. Following treatment with antimicrotubule drugs, a 
marked increase in GPC concentrations has been demonstrated (Sterin 2001). 
Increased GPC concentrations have also been demonstrated after treatment with the 
heat shock protein 90 inhibitor 17-AAG, the Bcr-Abl inhibitor imatinib and the PI3K 
inhibitor LY294002 (Beloueche-Babari 2006; Beloueche-Babari 2010a; Gottschalk 
2004). A treatment-induced increase in GPC concentration could lead to 
misinterpretation of changes in the tCho levels in cancers where GPC concentrations 
are in the same order of magnitude as PCho. Second, PCho concentrations have been 
shown to increase following treatment with 17-AAG or histone deacetylase inhibitors 
such as SAHA or LAQ824 (Chung 2003; Chung 2008; Sankaranarayanapillai 2006). 
Based on the data obtained in vitro and in animal models it is therefore not necessarily 
appropriate to associate a favorable treatment outcome with decreased tCho signal 
intensity.  
 
MRS has also been used to study glucose metabolism in various model systems. 
Using 13C-enriched glucose as tracer, regulation of both glucose and glutamine 
metabolism in cancer has been studied (Portais 1996). This allows both in vitro and in
vivo studies of how various anticancer treatments reduce the rate of glucose utilization 
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(Gottschalk 2004; Neeman 1989). Using ex vivo MRS, the improved sensitivity and 
spectral resolution allows detailed analyses of 13C-labeled tracers and their 
downstream metabolites. Regular 13C MRS has too low sensitivity to be directly 
translated to clinical applications. However, using a process called dynamic nuclear 
polarization (DNP), tracers may be hyperpolarized prior to injection, resulting in more 
than 10.000-fold in sensitivity. This allows dynamic magnetic resonance spectroscopy 
imaging, which has been used to study the reaction rates of key metabolic steps in 
cancer. The most widely used tracer is [1-13C] pyruvate, which is converted to [1-13C] 
lactate by the enzyme lactate dehydrogenase (LDH). In cancer, this conversion 
typically takes place at a higher rate than in normal tissue, and the rate of lactate 
production can therefore be used as a diagnostic tool or to monitor response to therapy 
(Brindle 2008; Golman 2006). This method is considered clinically applicable and 
may prove highly useful for detection and characterization of cancer in the future. 
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2 Objectives
 
The main objectives of the research presented in this thesis were to: 
 
- characterize orthotopic xenograft models of luminal-like and basal-like breast 
cancer using MRI and MRS. 
 
- identify MR-derived parameters associated with breast cancer aggressiveness 
using the xenograft models. 
 
- examine the relationship between metabolite profiles and expression of genes 
involved in regulation of metabolic pathways. 
 
- examine the relationship between histopathological analyses of vascularity and 
contrast agent kinetics in luminal-like and basal-like xenografts. 
 
- use MRI to assess changes in vascular function after antiangiogenic treatment. 
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3 Materials and methods 
3.1 Animal model 
The MAS98.12 and MAS 98.06 orthotopic xenograft models were previously 
established by surgical implantation of primary breast carcinomas in to the mammary 
fat pad of immunodeficient mice, as described in (Bergamaschi 2009). Serial 
transplantation of xenografts was performed at Oslo University Hospital, 
Radiumhosptitalet, and animals were transported from Oslo to Trondheim prior to the 
experiments. The tumors have a basal-like (MAS98.12) and luminal-like (MAS98.06) 
gene expression profile. The molecular characterization is described in (Bergamaschi 
2009).  The gene expression profiles are similar to that of the parent tumors, and have 
been stable over several passages. The animals were kept in pathogen-free conditions 
(individually ventilated cages, sterilized bedding). Room temperature (19-22qC), 
humidity (50-60%) and light dark/cycle (12/12h) were continuously monitored. The 
mice were given standard diet and sterilized water supplemented with 4 g/ml 17-E-
estradiol ad libitum. In Paper II, III and IV, experiments were performed using 
isoflurane anesthesia (delivered at a dosage of 5% for induction, 2% for maintenance 
anesthesia, in 67% N2 and 33% O2).  
All animal experiments were approved by the National Animal Research Authority.  
 
3.2 MR protocols 
In Paper I and II, HR MAS MRS was used for analysis of xenograft tissue samples 
(Bruker AVANCE DRX600 spectrometer). In paper I, the metabolite peak areas in 
the HR MAS MRS spectra were calculated by curve fitting (PeakFit, SeaSolve, San 
Jose, USA) and the metabolite concentrations were quantified using the ERETIC 
method, taking biopsy weight into account (Barantin 1997). The metabolite 
concentrations were compared between xenograft models using a two-sided t-test with 
a significance level of p < 0.05. In paper II, the spectra were converted to ASCII files 
and preprocessed to allow multivariate analyses (MATLAB, MathWorks, Natick, 
USA). Differences between the xenografts were analyzed using principal component 
analysis (Unscrambler, Camo, Oslo, Norway). The presence of 13C-labelled 
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metabolites was determined by comparing natural abundance spectra with spectra 
from animals which received 13C glucose. For comparison of glucose metabolism 
between the xenograft models, the peak area ratios between the observed metabolites 
were used.  
 
In paper III and IV, the animals were imaged using a 7T Bruker Biospec Avance 
70/20 small animal scanner (Bruker  Biospin, Ettlingen, Germany). A 72 mm volume 
coil was used for transmission and an actively decoupled quadrature mouse head 
surface coil was used for receiving. The animals were imaged using T1-weighted 
DCE-MRI with gadodiamide, and DW-MRI. In addition, high-resolution T2-weighted 
(pre-contrast) and T1-weighted (post-contrast) images were obtained to support slice 
orientation and to evaluate the final distribution of contrast agent in the tumors. The 
imaging setup is presented in Figure 8.   
 
 
Figure 8 Imaging set-up  
A) The animal bed. The green tube delivers heated air and the coil is immersed in the bed. B) An 
anesthetized mouse placed on an adapter with the tumor freely hanging down into the coil. C) The 
Biospec animal scanner with the bed positioned so that the tumor is located in the isocenter. 
Reproduced with permission from Else Marie Huuse, FUGE MIC, NTNU. 
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Technical details are presented in Table 1 and Table 2.  The DWI-MRI and DCE-MRI 
data were analyzed using in-house software developed in MATLAB (MATLAB, 
MathWorks, Natick, USA). The pre-contrast T1 values were obtained from a series of 
images with varying TR and used to calculate a contrast agent concentration/time 
curve for each voxel in the dynamic imaging series. The generalized compartment 
model proposed by Tofts et al (Tofts 1999) was then fitted to each voxel. Voxels 
without post-contrast signal enhancement (RSI1min < 1 or AUC1min < 0) were excluded 
from the pharmacokinetic modeling. The median Ktrans, ve and vp values were 
determined in all defined ROIs and compared across xenograft model and treatment 
using a two-sided t-test with a significance level of p < 0.05. ADC maps were 
calculated using a monoexponential fit of voxel signal intensities versus b-values 
(100, 300, 600 and 1000 s/mm2) and the median ADC values were calculated for each 
tumor. 
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Table 1 Detailed HR MAS MRS parameters used in Paper I and Paper II 
 
Paper I Paper II 
Xenografts Human tissue 
Xenografts 
1H 13C
Sequence 
single pulse 
(ereticpr.drx) 
cpmg 
(cpmgpr.drx) 
single pulse single pulse 
Spin rate (kHz) 5 5 5 5 
Temperature (qC) 4 4 4 4 
Water suppression  yes yes yes NA 
Flip angle 60q 90q 90q 60q 
Echo time (ms) NA 285 NA NA 
Sweep width (ppm) 16.7 16.7 12 210 
Acquisition time (s) 3.28 1.64 4.6 0.5 
No. averages 128 128 128 26000 
NA: not applicable 
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Table 2 Detailed MRI parameters for sequences used in Paper III and Paper IV 
 
DCE-MRI  
T1-map RARE 
RARE-factor 2 
TR (ms) 150, 750, 1500, 2500, 4500, 12000 
TE (ms) 7 
Dynamic series  
RARE-factor 4 
TR (ms) 300 
TE (ms) 7 
Temporal resolution (s) 4.8 
Number of repetitions 200 
Contrast agent injection  
Contrast agent Gadodiamide 
Dose (mmol/kg) 0.3 
Precontrast images 10 
Injection duration (s) 4 
Geometry  
Field of view (mm2) 22 x 22 
Matrix 64 x 64 
In plane resolution (mm) 0.34 
Slice thickness (mm) 0.6 
Number of slices 5 
Post-contrast T1-weighted image  
Sequence FLASH 
TR (ms) 300 
TE (ms) 5.4 
Field of view (mm2) 16 x 16 
Matrix 256 x 256 
In plane resolution (mm) 0.078  
Slice thickness (mm) 0.5 
DW-MRI  
Sequence Diffusion sensitized EPI 
b-values (s/mm2) 0, 100, 300, 600, 10001 
TR (ms) 3000 
TE (ms) 35 
Field of view (mm2) 15 x 15 
Matrix 64 x 64 
In plane resolution (mm) 0.23 
Slice thickness (mm) 1 
Number of averages 6 
RARE - rapid acquisition with refocused echoes; TR - repetition time; TE - echo time; EPI – echo planar imaging 
                                                 
1 Images obtained with b = 0 were not included in calculation of ADC values  
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3.3 Gene expression 
Gene expression analyses were performed on xenograft tissue from both models, and 
the expression of selected genes was combined with the metabolic profiles obtained 
by HR MAS MRS in Paper I and II. The expression of genes reported in these two 
studies was obtained from the same set of global gene expression profiles. The gene 
expression analyses were performed with support from the Dept. of Genetics, Institute 
for Cancer Research, Oslo University Hospital, Radiumhospitalet.  
 
After extraction from fresh frozen xenograft tissue, mRNA was hybridized to 44k 
microarrays (Agilent Whole Human Genome Oligo Microarrays, Agilent 
Technologies Inc, Santa Clara, USA). After processing of the raw signals, the 
expression data for genes listed in the glycerophospholipid (hsa:00564) and glycolysis 
(hsa:00010) pathways in KEGG (Kanehisa 2000) or otherwise known to be relevant 
for the choline and glucose metabolism was retrieved from the microarrays. The 
selected genes were tested for differential expression between the xenograft models 
using t-tests with correction for multiple testing. The global gene expression profiles 
have been deposited in NCBI's Gene Expression Omnibus (GEO) and are available to 
the public through GEO Series accession number GSE25915 (Edgar 2002). 
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3.4 Histopathology 
All histopathological examinations were performed in collaboration with the Dept. of 
Laboratory Medicine, Children’s and Women’s Health, NTNU. In addition, samples 
from Paper III and a subset of samples from Paper IV were stained and read at The 
Gade Institute, Section for Pathology, University of Bergen.  
 
In all studies, tumor tissue was harvested at the end of the experiment and fixed using 
neutral buffered formalin. The samples were subsequently embedded in paraffin and 
4m tissue slices were cut. These sections were then stained with HES according to 
the standard procedures of the department. HES-stained slices were examined under 
light microscope in Paper I and Paper II in order to verify the presence of viable 
cancer cells. In Paper III and IV, hypoxia was assessed by immunohistochemistry 
using the in vivo marker pimonidazole (Natural Pharmacia International Inc., 
Burlington, USA), which was injected intravenously prior to sacrifice of the animals. 
The stained sections were imaged at 2x magnification (Nikon Eclipse 80i microscope, 
Nikon Digital Sight DS-U1 camera, NIS-elements F3.0 software) using enough 
exposures to cover the entire tumor slice. Images were merged in Photoshop Elements 
6.0 (Adobe Systems Inc., San Jose, USA), converted to 32 bit b/w and the degree of 
hypoxia determined. ROIs enveloping the necrotic areas and the total tumor slice area 
were defined manually, and the hypoxic fraction was defined as the percentage of the 
stained area relative to the total area of the slice (ImageJ, National Institute of Health, 
USA). The mitotic activity of the tumors was assessed through the phosphohistone H3 
(PPH3), and reported as the number of mitotic cells per 10 FOVs. Staining of tumor 
vasculature was performed using CD34 and Ki67. All examinations of these samples 
were performed by an experienced pathologist. The stained sections were used to 
determine the mean microvessel density (MVD, CD34-positive counts/mm2) and the 
proliferative MVD (CD34+Ki67-positive counts/mm2). 
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4 Results 
 
4.1 Paper I 
Distinct choline metabolic profiles are associated with differences in gene 
expression for basal-like and luminal-like breast cancer xenograft models. 
The purpose of this study was to compare the choline metabolic profiles of a luminal-
like and a basal-like breast cancer xenograft model. In addition, the expression of 
genes involved in choline metabolism was compared between the models. Finally, the 
association between gene expression and metabolite profile was studied. 
 
The study was performed in luminal-like (MAS98.06) and basal-like (MAS98.12) 
orthotopic breast cancer xenograft tumors. These models have previously been 
established by direct transplantation of human primary tumor tissue, and are now 
serially propagated in SCID mice. The xenografts have maintained the gene 
expression profiles and hormone receptor status from the primary tumors. 
Quantitative metabolic profiles were obtained in fresh frozen tissue using HR MAS 
MRS, and the expression of genes involved in choline metabolism was retrieved from 
whole genome expression microarray analyses.  The metabolite profiles from the 
xenografts were compared with corresponding profiles from human breast cancer, 
sampled from patients with estrogen/progesterone receptor positive (ER+/PgR+) or 
triple negative (ER-/PgR-/HER2-) breast cancer.  
 
In the basal-like xenografts, glycerophosphocholine (GPC) concentrations were 
significantly higher than phosphocholine (PCho) concentrations. This pattern was 
reversed in luminal-like xenografts. These differences could be explained by lower 
expression of choline kinase alpha/beta, as well as higher PtdCho degradation 
mediated by higher expression of phospholipase A2 group 4A (PLA2G4A) in the 
basal-like model. The glycine concentration was also significantly higher in the basal-
like model. Although glycine could be derived from energy metabolism pathways, the 
gene expression data suggested a metabolic shift from PtdCho synthesis to glycine 
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formation in basal-like xenografts. In agreement with results from the xenograft 
models, tissue samples from triple negative breast carcinomas had higher GPC/PCho 
ratio than samples from ER+/PgR+ carcinomas. 
In this study, we demonstrated that differences in choline metabolite concentrations 
corresponded well with differences in gene expression. Using HR MAS MRS, we 
found distinct metabolic profiles in the xenograft models representing basal-like and 
luminal-like breast cancer. The same choline metabolite profiles were also observed 
in patient material from ER+/PgR+ and triple-negative breast cancer, suggesting that 
the xenografts are relevant model systems for studies of choline metabolism in 
luminal-like and basal-like breast cancer.  
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4.2 Paper II 
13C High Resolution Magic Angle Spinning MRS reveals differences in glucose 
metabolism between two breast cancer xenograft models with different gene 
expression patterns 
 
The purpose of this study was to examine the glycolytic activity in a luminal-like and 
a basal-like breast cancer xenograft model. This was accomplished by intravenous 
administration of [1-13C] glucose. Using HR MAS MRS, the levels of the parent 
tracer and its downstream metabolites was assayed. In addition, the expression of 
genes involved in glycolysis was compared between models. Finally, the relationship 
between glucose metabolism and gene expression was evaluated.  
 
The study was performed in luminal-like (MAS98.06) and basal-like (MAS98.12) 
orthotopic breast cancer xenograft tumors. Tumor tissue was collected both from 
untreated mice and mice that received an injection of 29 mg [1-13C] glucose 10 or 15 
minutes before harvesting of tumor tissue.  Glucose and its downstream metabolites 
lactate and alanine were determined by 13C HR MAS MRS, and the expression of 
genes involved in glycolysis was retrieved from whole genome expression microarray 
analyses.  
 
Both in natural abundance spectra (untreated animals) and in spectra from mice 
receiving [1-13C] glucose, the glucose/lactate and glucose/alanine ratios were found to 
be lower in luminal-like than basal-like xenografts. [3-13C] lactate and [3-13C] alanine 
were the predominant metabolites observed after [1-13C] glucose administration. [4-
13C] glutamate was identified in most luminal-like samples, but no other metabolites 
downstream of [1-13C] glucose were observed. The gene expression analyses 
demonstrated that most genes involved in glucose transport and glycolysis were 
higher expressed in the luminal-like than the basal-like xenografts. 
 
The study demonstrated that only a minimal fraction of the injected [1-13C] glucose 
was shunted to the TCA cycle for oxidative phosphorylation. The rate of lactate 
production in luminal-like xenografts was higher than in basal-like xenografts. The in 
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vivo growth rate of basal-like xenografts is significantly higher than luminal-like 
xenografts. Therefore, the study has shown that glycolytic activity and lactate 
production not directly reflect tumor growth rate. Microenvironmental factors such as 
hypoxia may stimulate to lactate production beyond the metabolic requirements for 
cellular proliferation and tumor growth.  
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4.3 Paper III 
In vivo magnetic resonance imaging and histopathological assessment of tumor 
microenvironment in luminal-like and basal-like breast cancer xenografts 
The purpose of this study was to explore tumor characteristics related to tumor 
microenvironment by in vivo MRI and histopathological markers, using two 
orthotopic breast cancer xenograft models reflecting luminal-like (MAS98.06) and 
basal-like (MAS98.12) gene expression profiles. Alterations associated with tumor 
growth and response to estradiol withdrawal were monitored by MRI and compared to 
histopathological measures of vascularization, hypoxia and markers of VEGF 
activation.  
 
Luminal-like (n=14) and basal-like (n=12) tumors (volume 200 - 600 mm3) were 
examined twice by dynamic contrast enhanced (DCE) and diffusion weighted (DW) 
magnetic resonance imaging (MRI), to monitor the effect of one week tumor growth 
or estradiol withdrawal. The impact of tumor size was investigated using large basal-
like tumors (n=7, volume >1400 mm2). The transfer constant (Ktrans) reflecting 
vascular permeability and perfusion, extracellular and extravascular volume fraction 
(ve) and blood plasma volume fraction (vp) were estimated using two-compartment 
modelling of the contrast agent uptake in the tumor. The apparent diffusion 
coefficient (ADC) of water in the tumor was calculated from the DW-MRI data.  
 
Ktrans, vp and ADC were significantly higher in basal-like compared with luminal-like 
tumors (all P<0.01). The histopathologically measured vascular proliferation index 
(VPI) confirmed these findings, showing twofold higher values among the basal-like 
tumors. No changes in MRI extracted parameters were found after 6 days of tumor 
growth. Estradiol withdrawal induced a significant increase in Ktrans, ve and ADC (all 
P<0.05) in luminal-like xenografts, corresponding with an increase in VEGFR2 
activation, which is likely to cause increased tumor vessel permeability.  
 
The study confirmed the potential of functional MR methods to map changes in tumor 
vasculature and microenvironment in vivo, and demonstrated significant differences 
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in tumor architecture and vascular function between the luminal-like and basal-like 
xenografts. 
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4.4 Paper IV 
Low-molecular contrast agent DCE-MRI and DW-MRI in early assessment of 
bevacizumab and doxorubicin therapy in breast cancer xenografts  
The main purpose of this study was to assess vascular responses to the antiangiogenic 
agent bevacizumab in luminal-like (MAS98.06) and basal-like (MAS98.12) breast 
cancer xenografts using DCE-MRI and DW-MRI. To increase the clinical relevance 
of the study, a low-molecular Gd-based contrast agent (Omniscan®) was used. 
Animals were also treated with doxorubicin, in order to identify the effects 
specifically associated with antiangiogenic treatment. 
 
Animals carrying luminal-like (MAS98.06) or basal-like (MAS98.12) xenografts 
were treated with bevacizumab (5 mg/kg ip.), doxorubicin (8 mg/kg iv.) or a 
combination of both drugs. The animals were imaged on a 7T animal scanner before 
and 3 days after treatment. Signal intensity curves obtained using DCE-MRI were 
assessed voxel-by-voxel using nonparametric and parametric methods. The spatial 
variation in tumors was assessed by defining ROIs both in central and peripheral 
regions of the tumors. Histopathological vascularization analyses were performed in 
order to correlate MRI findings with changes in vascular architecture and function. In 
addition, changes in hypoxic fraction and mitotic activity were determined.  
 
In all treatment groups, a response to therapy was demonstrated using DW-MRI. 
Treatment-related increases in ADC were found both in central and peripheral regions 
of the tumors. DCE-MRI data demonstrated marked differences between pre-
treatment and post-treatment signal intensity curves in bevacizumab-treated animals 
or animals receiving combination therapy. Doxorubicin treatment had little impact on 
contrast agent kinetics, except a late signal enhancement in basal-like xenografts 
indicative of necrosis. Increased RSI1min was observed in all animals receiving 
bevacizumab or combination therapy. In addition, increased ve was seen in basal-like 
xenografts whereas increased vp was seen in luminal-like xenografts. The change in 
DCE-MRI parameters was more prominent in central tumor regions. In vascular 
histopathological analyses, both the total number of microvessels (MVD) and the 
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number of proliferating vessels (VPI) were decreased in basal-like xenografts after 
treatment with bevacizumab or combination therapy. A similar trend was seen in 
luminal-like xenografts.  
 
The study demonstrated that DCE-MRI using a clinically available low-molecular 
contrast agent could detect changes in tumor vascular function after antiangiogenic 
treatment. Both bevacizumab and combination therapy caused increased contrast 
agent uptake in central regions of the tumor. Doxorubicin alone did not cause 
significant changes in vascular function. The changes suggested improved perfusion 
or reduced interstitial fluid pressure, consistent with transient normalization of tumor 
vasculature following antiangiogenic therapy. Histopathological analyses verified the 
antiangiogenic effect of bevacizumab and that changes in DCE-MRI parameters were 
related to vascular function rather than the number of blood vessels.  
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5 Discussion
The main objective of this thesis was to evaluate how MRI and MRS can be used to 
describe architectural, functional and molecular differences between two genetically 
and biologically different breast cancer xenograft models. The two models represent 
basal-like (MAS98.12) and luminal-like (MAS98.06) subtypes of breast cancer, and 
are associated with poor and good prognosis, respectively. It is therefore possible to 
determine how MRI and MRS parameters are associated with tumor growth rate, 
histopathological features, microenvironmental factors and the genetic background of 
two xenograft models representing different breast cancer subtypes. Characterization 
of the basal-like and luminal-like xenografts, both with respect to their biology and 
MRI/MRS parameters is an important step in establishing the xenografts as relevant 
model systems for human breast cancer. The models are representative of clinical 
luminal-like and basal-like breast cancer both with respect to vascularization and 
choline metabolism (Moestue 2010; Nalwoga 2011), and may therefore be valuable in 
evaluation of new drugs. In this context, understanding the biology of basal-like 
breast cancer and its response to treatment is particularly important, as this disease is 
associated with poor prognosis and currently lacks targeted alternatives for 
pharmacotherapy. Understanding the regulation of key metabolic pathways is an 
independent objective of the thesis. Both choline metabolism and glycolysis are 
considered to contain potential targets for anticancer therapy, but the regulation of 
these pathways is predominantly studied in vitro and the association between breast 
cancer subtypes and metabolic profiles is not previously studied. Finally, the thesis 
illustrates how a wide range of MR protocols can be used to characterize cancer 
subtypes. The versatility of the MR technology allows evaluation of several different 
aspects of tumor biology, increasing the possibility of identifying clinically relevant 
biomarkers.   
 
5.1 Animal models 
In contrast to cell cultures or other in vitro methods for studying the growth of cancer 
cells, xenograft tumors mimic the entire tumor system. It is widely recognized that 
tumors consist of several tissue types, including both stromal components and 
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vascular tissue, which have reciprocal effects on each other and generate a model-
specific tumor microenvironment. Studies of cancer using xenograft models enable 
control of factors that affect tumor progression and response to treatment in a 
physiologically relevant context. However, the influence from vascular and stromal 
components and the tumor microenvironment must be taken into account when 
interpreting data from xenograft studies. Parameters such as hypoxia, perfusion and 
interstitial fluid pressure have impact on both tumor metabolism and response to 
therapy, and the results from MRI/MRS studies can therefore be used to evaluate the 
impact of microenvironmental parameters.  
 
All studies included in the thesis are performed using the same breast cancer 
xenograft models. These models are established directly from primary carcinomas of 
breast cancer patients, and represent basal-like and luminal-like breast cancer. The 
xenografts grow orthotopically. This is considered to increase the clinical relevance as 
both tumor-stroma interactions and vascularization depend on the location of the 
xenograft (Vargo-Gogola 2007). The xenograft models have in general maintained 
both the gene expression profile and phenotype/receptor expression of the parent 
tumors. However, although the subtyping of breast cancer include both a luminal A 
and a luminal B subtype (Perou 2000), the exact subtype of the luminal-like xenograft 
model remains unknown. The clinical features of the luminal-like xenograft 
(estradiol-dependent growth, ER+/PgR+ phenotype) can be associated with the 
luminal-A subtype. However, the gene expression clustered tightly with the luminal-B 
subtype (Bergamaschi 2009). Expression profiles from the extracellular matrix 
clustered with the luminal-A subtype for the primary tumor. In the xenografts, where 
the extracellular matrix predominantly is of murine origin, this profile was shifted to a 
luminal-B-associated profile. This illustrates the complexity of subclassification of 
xenografts based on gene expression profiles. The luminal A subtype is generally 
associated with a more favorable outcome than the luminal B subtype (Sorlie 2001). 
Subtyping of xenografts based on gene expression profiling should be interpreted with 
caution, as the human stromal components are replaced with stromal components 
from the mice. In microarrays based on human genes, the expression of stromal genes 
from the mouse generally cause signal loss which in turn leads to underestimation of 
genes associated with the extracellular matrix. 
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Generally, establishing breast cancer from primary patient tumors is challenging, with 
a success rate of around 10%. Establishing ER+/PgR+ xenografts is especially 
difficult, as demonstrated by Marangoni et al, who obtained 25 xenograft models 
from 200 clinical tumor samples (Marangoni 2007). Of these 25, only one model was 
ER+, reflecting the strong selection bias toward aggressive tumors. However, 
xenograft models based on primary tumors offers an advantage compared to models 
based on cultured cell lines. The transplanted xenograft tumors contain numerous cell 
clones representing the diversity of cells present in human breast carcinomas. The 
cells in the xenografts are to some extent differentiated, and stromal components from 
the primary tumors may be carried along together with the cancer cells. In contrast, 
cultured cells generally have been selected for their ability to grow in artificial media 
and represent highly homogeneous cell populations. The xenografts are grown 
orthotopically, in the mammary fat pad. Compared to subcutaneously grown tumors, 
the mammary fat pad is considered to provide a more relevant microenvironment for 
breast tumors. Despite the controversy regarding the molecular subtype of the 
luminal-like xenograft, it is less aggressive than the basal-like xenograft. The slower 
tumor growth rate and lower level of angiogenesis, in addition to the profound 
addiction to a dietary estradiol supplement, distinguishes it clearly from the basal-like 
xenograft. Thus, the models are considered clinically relevant representations of 
human breast cancer heterogeneity, as they describe extremes in animal models of 
breast cancer with respect to aggressiveness.  
 
To explore similarities in metabolic profile between the xenograft models and human 
breast cancer of corresponding subtype, spectra from patients with triple-negative 
breast cancer were compared with spectra from the basal-like xenografts. Although 
there is general consensus that these two entities overlap to a significant degree, the 
relationship between triple-negative and basal-like breast cancer is a topic of debate 
(Badve 2011a). Triple-negativity is a phenotype determined from receptor expression 
whereas basal-like breast cancer is determined from gene expression analysis. There 
is no internationally accepted definition for basal-like breast cancer. Using gene 
expression microarrays, a basal-like gene signature has been proposed (Perou 2000). 
However, classification of biopsies according to this gene signature may be difficult.  
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Cancers with basal-like gene expression may have significant variation in their 
morphological features. In general, they lack or have low ER/PgR levels, lack HER-2 
amplification and express proteins usually found in the basaloid cells of the normal 
breast. In contrast, there is little controversy regarding the definition of triple-negative 
breast cancer. Still, different pathology laboratories may have different thresholds for 
scoring ER/PgR expression. Some laboratories require more than 10% ER-positive 
cells in order to classify a sample as ER positive, whereas other laboratories score 
samples as ER+ in the presence of >1% positive cells (Gown 2008). Some 
laboratories count only cells with nuclear staining whereas others also define 
cytoplasmic staining as a positive finding. Due to the numerous similarities between 
the two terms, basal-like breast cancer and triple negativity has often been used 
interchangeably (Rakha 2009). In general, however, it has been shown that tumors 
with triple-negative phenotype are classified as basal-like in more than 90% of cases 
(de Ronde 2010; Kreike 2007). It should be noted that the fraction of basal-like 
tumors exhibiting non-triple-negative phenotype in general is as high as 20-30% 
(Badve 2011b). The existing knowledge suggests that triple negative phenotype may 
be a valid surrogate marker for basal-like molecular subtype, whereas basal-like 
subtype is not a valid surrogate marker for triple negative phenotype.  
 
5.2 Experimental protocols 
5.2.1 HR MAS MRS
The metabolic profiles of the basal-like and luminal-like xenografts were studied 
using 1H HR MAS MRS and 13C HR MAS MRS. Due to its reproducibility and high 
spectral resolution, 1H HR MAS MRS has become an important tool in metabolic 
profiling of cancer. In contrast to destructive MRS methods, HR MAS MRS allows 
subsequent analyses of intact tissue specimens. Histopathological evaluation of tissue 
samples after MRS analysis can ensure that the metabolic profile is obtained in viable 
cancer tissue. In paper II, we use 13C HR MAS MRS for tracing 13C-labeled glucose 
and its downstream metabolites. Although the sensitivity is a limitation, this method 
allows functional studies of metabolic processes. Such knowledge may be important 
for future studies of hyperpolarized tracers.  
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The metabolite concentrations in Paper I were quantified using the ERETIC method. 
The performance of the method has been evaluated using calibration standards and 
comparing with the commonly used internal standard TSP (Sitter 2010a). This 
demonstrated that the precision and accuracy of ERETIC is good, with a maximum 
relative error of 8.4%. This suggests that the variability in metabolite concentrations 
(relative standard deviation 25-66%) in the xenografts is due to intersubject variation 
rather than analytical inaccuracy. Such variation may reflect heterogeneous 
microenvironmental conditions within the tumors. 
 
In Paper II, the main objective was to detect [1-13C] glucose and any downstream 
metabolites. Quantification of metabolites was not performed, and metabolite ratios 
were instead used for evaluation of metabolic activity. However, comparing 
metabolite ratios at two different time points suggested that the luminal-like 
xenografts had higher glycolytic rate. This hypothesis was corroborated using gene 
expression profiling.  
 
In both Paper I and Paper II, it was decided to perform HES staining and score the 
amounts of viable tumor tissue, necrosis and adipose/other tissue using light 
microscopy. Although xenograft tumors are more homogenous than human tissue 
samples, this allows the elimination of samples that are not representative due to 
extensive necrosis or the presence of non-tumor tissues. However, the 
histopathological examinations demonstrated that all samples predominantly 
consisted of viable tumor tissue, indicating that the results are not influenced by errors 
in tissue sampling. This serves as a quality control of the data, in contrast to 
destructive methods such as extraction procedures, which do not allow post-analysis 
evaluation of the specimens.  
 
 
5.2.2 DCE-MRI and DW-MRI 
DCE-MRI is a widely used method for in vivo characterization of tumor vasculature. 
As described in the introductory sections, tumor vasculature is chaotic, immature and 
leaky. Therefore, kinetic analysis of contrast agent disposition can distinguish tumor 
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vasculature from that of neighboring tissue. In Paper III and IV, a spin-echo sequence 
(MSME, Bruker Paravision 3.0) was used to acquire the dynamic image series. The 
sequence was accelerated using the RARE-method, with an acceleration factor of 4. 
This resulted in a temporal resolution of 4.8 seconds with a voxel size of 0.34 x 0.34 x 
0.60 mm. The high temporal resolution allowed pharmacokinetic modelling of a 
clinically available, low-molecular contrast agent (gadodiamide, Omniscan®). 
Macromolecular contrast agents have slower pharmacokinetics and DCE-MRI can be 
performed with lower temporal resolution. However, such agents are not available for 
routine clinical use, which encouraged the use of gadodiamide. Due to its size, 
gadodiamide is not a freely diffusible tracer. Instead, its translocation from blood 
vessels to extravascular space is restricted both by perfusion and vessel permeability. 
This must be taken into account when the DCE-MRI data are interpreted. For 
perfusion measurements, freely diffusible tracers are more suitable as they leak 
rapidly into the EES. When equilibrium in contrast agent concentration between the 
blood pool and the EES is reached immediately, Ktrans represents only the tissue 
perfusion. For macromolecular contrast agents, extravasation depends on the tumor 
vessel permeability, and Ktrans is then a measure of the permeability. Using 
gadodiamide, changes in Ktrans reflect both changes in perfusion and permeability. Its 
physiological meaning can therefore vary both between model systems and during 
tumor progression. Changes in interstitial fluid pressure may also influence the Ktrans 
value (Gulliksrud 2009) due to changes in intratumoral conductivity.  The DCE-MRI 
data (Paper III and Paper IV) were analyzed both using two-compartment kinetic 
modelling and empirical methods. If these two approaches can extract similar 
information from the experimental system, empirical methods are preferred in the 
clinical setting due to their simplicity and methodological robustness. When these two 
approaches provide coherent data, the empirical methods may also be considered an 
internal quality control of the pharmacokinetic modelling. To allow comparison of the 
pharmacokinetic parameters with other studies, Tofts’ consensus model was used 
(Tofts 1999).  To ensure compliance with the requirements of the two-compartment 
model, voxels without signal enhancement after injection of contrast agent (RSI1min<1 
or AUC1min <0) were excluded from the modelling. In tumor xenografts, such voxels 
are typically associated with necrotic tissue, and trying to fit the 2-compartment 
model to such voxels often results in poor fit and unphysiological model parameters. 
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In individual tumors, from 10 to 25% of voxels were typically filtered out using this 
approach. The fraction of voxels with no signal enhancement 1 minute after 
administration of contrast agent was significantly reduced in animals treated with 
bevacizumab (Paper IV), suggesting that the fraction of filtered voxels may serve as a 
biomarker for altered vascular function.  
 
An averaged population AIF was used in both Paper III and Paper IV. Ideally, an 
individual AIF should be obtained for all study subjects in order to improve the model 
fit. However, this is difficult to obtain as it requires a high spatial resolution in order 
to avoid partial volume effects and a global excitation pulse to avoid flow artifacts. In 
addition, a large blood vessel must be present in the FOV. It is in general difficult to 
separate individual biological variation from variation induced by measurement 
uncertainty. Orthotopic breast cancer xenografts are not fed by a single blood vessel, 
but by a number of different vessels that have been recruited from the mammary fat 
pad. The blood supply to the tumor depends on its ability to recruit these vessels and 
individual variation in the perfusion must be expected. Therefore, determining the 
AIF in a large vessel distant to the tumor on an individual basis may not necessarily 
reflect the actual arterial input function of the tumor. Due to the difficulty of obtaining 
an adequate individual AIF, it is generally accepted to use a relevant population AIF. 
When the appropriate precautions are taken, there is good correlation between the 
DCE-MRI pharmacokinetic parameters calculated from population and individual 
AIF (Loveless 2011). A population AIF should, as far as practically possible, be 
obtained in the same strain of animals and under identical experimental conditions as 
in the main experiment. In this work, an AIF modeled in-house in a similar strain of 
mice was used, potentially reducing the accuracy of the pharmacokinetic modeling.  
 
DW-MRI is evolving into a tool for both tumor detection, staging and monitoring of 
response to treatment (Padhani 2009). It is generally recommended to use b-values d 
1000 s/mm2 and perform a monoexponential curve fit in order to calculate the ADC. 
However, low b-values (b d 100 s/mm2) are sensitive to perfusion and therefore 
induce a bias in the diffusion measurements. Therefore, images obtained with b = 0 
were excluded from ADC calculations. The remaining b-values (100, 300, 600 and 
1000 s/mm2) are thought to represent extra- and intracellular diffusion within the 
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tumors. The DW-MRI images were obtained after the DCE-MRI images, and it has 
been shown that ADC values obtained after contrast agent administration are slightly 
lower than pre-contrast ADC values (Yamada 2002). The order of imaging sequences 
was partly chosen to avoid blood clotting in the tail vein cannula. In addition, the 
same order has been used in clinical breast examinations for improved lesion 
detection. As the DW-MRI images were obtained approximately 45 minutes after 
contrast injection in all animals, the effects of residual contrast agent was assumed to 
be similar in all animals. Therefore the order of the imaging sequences was not 
considered to influence the experimental findings.   
 
5.3 Assessment of glucose and choline metabolism 
Paper I and II concerns the metabolic profile of the basal-like and luminal-like 
xenografts. In particular, the choline metabolism and the glycolysis were studied in 
detail. These two metabolic pathways were selected for several reasons. Firstly, they 
have been shown to be abnormally regulated in cancer. Secondly, they contain 
metabolites that can be observed using MRS. Finally, drugs interfering with these 
metabolic pathways have been shown to reduce the growth rate of solid tumors in 
preclinical studies.  
 
Choline phospholipid metabolism is altered across a wide range of cancers. The most 
consistent abnormality is elevated PCho concentration and increased tCho signal in 
vivo (Glunde 2011). These changes have been associated with overexpression of 
choline kinase and phospholipase C (Glunde 2004). It is frequently stated that breast 
cancer cells switch from a high GPC/low PCho ratio to a low GPC/high PCho ratio 
during malignant transformation (Glunde 2011; Podo 1999). This is an interpretation 
of in vitro studies reported by Aboagye et al, where the concentrations of individual 
choline metabolites in an array of cell lines ranging from immortalised human 
epithelial breast cells to aggressive, metastatic breast cancer cell lines were assessed 
(Aboagye 1999). These findings have been extended to clinical in vivo MRS breast 
cancer, where a high tCho signal is associated with malignant disease, and a reduction 
in tCho is a marker for response to neoadjuvant therapy (Baek 2009; Gillies 2005).  
This consensus has been questioned on several grounds. Firstly, the metabolic profiles 
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obtained in cultured cell lines are not fully consistent with ex vivo profiles obtained 
from clinical cancer samples using HR MAS MRS. In clinical cancer samples, 
GPC:PCho ratio > 1 has been reported (Sitter 2006). In prostate cancer, GPC 
concentration is positively correlated to tumor grade (Keshari 2011). Secondly, it has 
been shown that the experimental conditions may have a profound effect on the 
metabolic profile of cultured cells (Morse 2009). Finally, it has been shown that 
microenvironmental factors contribute to the regulation of choline phospholipid 
metabolism (Eliyahu 2007a). These data suggest that in vitro metabolic profiles may 
not be representative for human disease. The use of tCho in therapy monitoring has 
also been questioned, since several studies have demonstrated that anticancer agents 
actually cause increased concentrations of PCho and/or GPC (Moestue 2011a; Sterin 
2001).  
 
As the role of choline phospholipid metabolism in breast cancer is not understood in 
detail, HR MAS MRS was performed on tissue samples from basal-like and luminal-
like xenografts, in order to evaluate metabolic profile. The two models had significant 
differences in the concentration of PCho, GPC and glycine, and we therefore 
compared the expression of genes involved in this metabolic pathway. Synthesis of 
these datasets showed that the gene expression explained some of the differences in 
metabolic profile. The luminal-like xenografts had higher PCho concentration, which 
was attributed to higher choline kinase expression. The higher GPC concentration in 
basal-like xenografts could be explained by a higher expression of PLA2, in particular 
the Group IVa isoenzyme. Expression of genes involved in conversion of choline via 
betaine to glycine was also higher in the basal-like xenografts, possibly explaining the 
higher glycine concentration in this model. Another plausible explanation is 
overexpression of the PHGDH enzyme, which diverts the metabolic flux from 
glycolysis into serine and glycine production (Seton-Rogers 2011). Overexpression of 
this gene is associated with triple negative/basal-like breast cancer, which is in 
accordance with the high glycine levels observed in breast cancer patients with poor 
prognosis (Giskeodegard 2010; Sitter 2010b). This study therefore identified possible 
genes that are of importance for regulation of choline phospholipid metabolism. The 
metabolic profiles from the xenograft models were compared with corresponding 
human breast cancer samples, demonstrating that the xenograft models to a large 
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degree were representative of the metabolic profiles found in human disease. Out of 
necessity, the samples from basal-like and luminal-like xenografts were compared to 
clinical triple negative and ER+/PgR+ breast cancer, respectively. This was 
considered appropriate as more than 90% of triple negative breast cancers also can be 
assigned to the basal-like subtype. The ER+/PgR+ breast cancers were also classified 
as luminal-A using gene expression profiling, demonstrating that the molecular 
profiles were similar to that of the luminal-like xenograft model.  
 
This study suggested that molecular subtypes of breast cancer may be associated with 
different metabolic profiles. It also suggested a number of enzymes that may be 
responsible for the differences in metabolic profile. The regulation of choline 
phospholipid metabolism can, however, not be deduced from the study. Differences in 
metabolic profile could either be associated with differences in oncogenic signal 
transduction, or with differences in the tumor microenvironment. As shown in paper 
III, the luminal-like xenografts are more hypoxic than the basal-like xenografts. 
Hypoxia induces HIF-1 activity, which in turn has been shown to upregulate the 
activity of choline kinase and increase PCho concentration (Glunde 2008). Therefore, 
it is possible that the difference in metabolic profile is due to microenvironmental 
differences rather than being an intrinsic property of luminal-like xenograft. On the 
other hand, similar profiles are found in both xenografts and human samples, 
suggesting that intrinsic factors also are of importance.  
 
The data obtained in Paper I suggests that a high GPC concentration may be 
associated with aggressive breast cancer, adding complexity to the current hypothesis 
that PCho rather than GPC is associated with malignant transformation. The paper 
also suggests that in vivo 1H MRS is unable to distinguish these subtypes based on the 
tCho signal. tCho levels are similar in both models despite the profound difference in 
metabolic profile, and 31P MRS may be a better approach for studies of choline 
metabolism in breast cancer diagnosis and therapy monitoring. 
 
One of the most prominent metabolic abnormalities in cancer is a high rate of aerobic 
glycolysis, where glucose is converted to lactate even under normoxic conditions 
(Warburg 1924). The low ATP yield is compensated by a high metabolic flux (Vander 
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Heiden 2009). This way, cancer cells can produce energy while conserving carbon for 
production of proteins and nucleotides, as required to maintain a high rate of 
proliferation. As shown in Figure 9, the oncogenic signalling pathways that regulate 
choline metabolism have also been shown to regulate glucose metabolism (Elstrom 
2004; Lock 2011; Tennant 2009; Yeung 2008).  
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Figure 9 Oncogenic regulation of choline and glucose metabolism 
The PI3K/AKT/MTOR signalling pathway regulates both choline and glucose metabolism by 
controlling the activity of key enzymes on different levels in both these metabolic pathways. Elliptic 
shapes represent proteins whereas rectangular shapes represent metabolites or metabolic pathways. 
Solid lines represent metabolic conversion, dotted lines represent the regulatory effects from oncogenic 
signalling transducers (red) on metabolic enzymes (blue). Transcription factors such as Myc or HIF-1 
are also regulated by microenvironmental factors. Reproduced with permission from Moestue et al,
Mol Oncol 2011; 5 (3); 224-241. 
 
Glucose metabolism in cancer can be studied using various MRS techniques both in 
vitro and in vivo.  High resolution MRS can be applied to cell cultures, tissue samples 
and extracts. Proton spectroscopy is routinely used in cancer diagnosis and 
management, and assessment of lactate production can be performed during a clinical 
MR examination. Advances in MRS methodology combined with increased interest in 
glycolysis as a therapeutic target can lead to increased use of in vivo lactate MRS 
assessment. Other metabolites in the glycolysis are present in low concentrations and 
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are seldom considered as biomarkers in proton spectroscopy.  Most studies of the 
glycolytic pathway use 13C MRS for tracing the metabolic fate of [1-13C] glucose or 
other isotopically enriched substrates. 13C MRS has also been used to study glucose 
metabolism in vivo in cancer (Kurhanewicz 2008; Wijnen 2010).  Following 
administration of 13C-enriched substrates to tumor-bearing animals, the fate of the 
substrates can be studied taking tumor microenvironmental factor into account.  
However, 13C MRS is not yet routinely used in clinical diagnosis or management of 
cancer.  This may change as new spectroscopic techniques, such as hyperpolarized 
13C MRSI, are further developed.  
 
The objective of Paper II was to establish a protocol for 13C HR MAS MRS, which 
allows analysis not only of [1-13C] glucose metabolism but also any other 13C-
enriched substrates. In contrast to 1H MRS, this allows evaluation of metabolic flux 
since the levels of both the parent compound and its downstream metabolites can be 
assayed. This could allow evaluation of a wide range of substrates for in vivo 
application, including hyperpolarized MRS. Abnormal glycolytic activity has 
repeatedly been observed in cancer, and it has also been demonstrated that the 
glycolytic rate can be modulated by cytotoxic drugs, direct glycolytic inhibitors or, in 
the case of breast cancer, endocrine treatment (Ben-Horin 1995; Neeman 1989; 
Poptani 2003).  However, the association between glycolytic rate and malignancy is 
not completely understood. Lactate concentration has been suggested as a biomarker 
for malignant transformation both in brain and prostate cancer (Tessem 2008; 
Walenta 2004). There is also considerable interest in glycolytic inhibitors as 
anticancer agents (Tennant 2010). By tracking the fate of [1-13C] glucose in basal-like 
and luminal-like xenografts, evaluation of the relationship between tumor growth rate 
and glycolytic flux could be assessed. The 13C spectra demonstrated that virtually all 
the administered glucose was converted to alanine and lactate. However, small 
amounts of [4-13C] glutamate were also detected in the luminal-like xenografts. This 
suggests that the TCA cycle is intact but downregulated. Evaluation of [1-13C] 
glucose, [3-13C] alanine and [3-13C] lactate levels in the xenografts suggested that 
both models produced significant amounts of both alanine and lactate within 10 
minutes of glucose administration. The amount of both these metabolites was 
increased at 15 minutes, demonstrating that the samples were collected during a 
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period of active tracer metabolism in the cancer cells. Interestingly, only negligible 
glucose levels were observed in luminal-like xenografts. This suggests that the 
glycolytic rate in these tumors is higher than the glucose uptake rate, which was not 
the case for the basal-like xenografts. The total lactate amounts were similar in the 
two models. As most glycolytic genes, including glucose transporters, hexokinase and 
lactate dehydrogenase were higher expressed in luminal-like xenografts, the combined 
data strongly suggest higher glycolytic rate in the luminal-like xenografts. This means 
that glucose consumption rate not necessarily is associated with tumor growth rate. 
Instead, it suggests that modulation of glucose metabolism by microenvironmental 
factors may be a determinant factor. The luminal-like xenografts have poorer 
vascularization and higher hypoxia levels than the basal-like xenografts. This may 
activate HIF-1 which is known to stimulate glycolysis. The mapping of glucose 
metabolism in these models provides a fundament for studies of inhibition of 
glycolysis as a therapeutic strategy. If the luminal-like xenografts are addicted to 
aerobic lactate production, glycolytic inhibitors may potentially be more effective in 
this model.  
 
5.4 Assessment of bevacizumab treatment 
In Paper III, the basal-like and luminal-like xenografts were examined by MRI and 
histopathology to describe the vascular and microenvironmental characteristics of the 
tumors. The effect of tumor growth and estradiol withdrawal was monitored by 
imaging the same animals with a 7-day interval. Both DCE-MRI and DW-MRI 
showed differences between the xenografts, and the histopathological evaluation 
contributed greatly to the interpretation of these differences. Furthermore, the paper 
provided a fundament for assessment of changes in vascular function after treatment 
with the VEGF inhibitor bevacizumab. Basal-like xenografts had higher Ktrans and vp 
than luminal-like xenografts, which is in accordance with the higher MVD and 
proliferative MVD (pMVD) observed in basal-like xenografts. Both a high Ktrans and 
high MVD/pMVD are associated with poor prognosis in cancer. These results show 
that DCE-MRI can be used to noninvasively evaluate the vascularity of solid tumors, 
which may be of value in breast cancer risk stratification (Gravdal 2009; Pickles 
2009; Stefansson 2006; Turnbull 2009).  The study also demonstrated that contrast 
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agent pharmacokinetics did not change significantly over a 7-day interval. However, 
by comparing large tumors (> 1500 mm3) with medium-sized tumors (200-600 mm3), 
a reduction in vascularization with concomitant hypoxia and reduced Ktrans values was 
observed. The differences in tumor volume represent a3 weeks (basal-like xenografts) 
and 6-13 weeks (luminal-like xenografts) of growth, demonstrating that the tumor 
volume is an important experimental factor that should be taken into account in 
design and interpretation of preclinical MRI studies. The changes in DCE-MRI 
parameters after estradiol withdrawal suggested that the imaging protocol was 
adequate for assessment of changes in vascular function following treatment with 
anticancer drugs.  
 
In Paper IV, the effect of the anti-VEGF antibody bevacizumab was evaluated using 
DCE-MRI and DW-MRI. Bevacizumab has been approved for clinical use in several 
cancers, including breast cancer. However, its impact on patient survival has so far 
been less than anticipated when the concept of antiangiogenic treatment first was 
conceived. Therefore, it is a need for noninvasive methods that can discriminate 
between responders and non-responders. Identification of the patient subpopulations  
which will benefit from a drug can increase its clinical utility. Previous studies using 
macromolecular contrast agents have shown that bevacizumab treatment reduce the 
Ktrans values. As the transcapillary transport of macromolecular contrast agents mainly 
depend on vascular permeability, these findings show that bevacizumab reduces 
tumor vessel leakiness. However, such contrast agents are not approved for clinical 
use. It has also been shown that bevacizumab treatment reduces interstitial fluid 
pressure (IFP), possibly due to less leakage of serum proteins into the interstitium 
(Dickson 2007). This suggests that bevacizumab-induced changes should be 
imageable using low-molecular contrast agent DCE-MRI. An inverse correlation 
between IFP and transcapillary transport of gadodiamide has previously been reported 
(Gulliksrud 2009).  
In basal-like xenografts, bevacizumab treatment has been shown to significantly 
inhibit tumor growth (Lindholm EM, submitted to Br J Cancer 2011). In Paper IV, it 
was shown that the MVD and pMVD in basal-like xenografts decreased significantly 
after bevacizumab treatment. A similar trend was seen in the luminal-like xenografts. 
In contrast, the DCE-MRI data demonstrated increased contrast agent uptake in both 
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xenografts. The increase was greatest in the central regions of the tumors, whereas 
peripheral areas showed only minor changes. In addition, the fraction of non-
enhancing cells decreased significantly following bevacizumab therapy. These 
findings suggest that low-molecular contrast agent DCE-MRI after bevacizumab 
therapy reflects changes in vascular function rather than changes in MVD. 
Furthermore, as studies using macromolecular contrast agents have shown that 
bevacizumab reduces the vascular permeability, the changes observed in this study 
must be caused by improved perfusion, particularly in central tumor regions. Similar 
changes were found in both basal-like and luminal-like xenografts, suggesting that 
VEGF blockade may have a profound effect on vascular function also in the absence 
of reduced MVD or pMVD.  
 
Although vascular normalization following bevacizumab therapy may be transient, 
noninvasive methods for monitoring vascular function may be useful for determining 
metronomic drug dosing regimens (Jain 2005). It has previously been shown that anti-
VEGF therapy can enhance the delivery of anticancer drugs in solid tumors (Dickson 
2007). The findings in Paper IV suggest that increased perfusion in central tumor 
regions may enhance the delivery of chemotherapeutic drugs. In this setting, DCE-
MRI could be used to identify the optimal time point for administration of 
chemotherapy. 
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6 Conclusions and future perspectives 
In this thesis, basal-like and luminal-like breast cancer xenograft models have been 
characterized using MRI/MRS in combination with histopathology and gene 
expression analysis. Several MR-derived parameters were associated with the 
aggressiveness of the xenografts, including high GPC and glycine concentration and 
high Ktrans and vp values.  
 
The work has established the xenografts as relevant model systems for therapy 
monitoring studies in basal-like and luminal-like breast cancer. In addition, several 
interesting aspects of breast cancer molecular biology have been revealed using MRS. 
Firstly, we have shown that previous theories regarding choline metabolism may be 
too simplistic and not covering the entire range of breast cancer heterogeneity. While 
it has been suggested that high GPC/PCho ratio is associated with normal breast tissue 
and that malignancy predominantly correlate with PCho concentration, the findings in 
basal-like xenografts suggest that high GPC can be found in aggressive breast cancer 
subtypes. This indicates that follow-up studies should be performed, as the choline 
cycle may contain several targets for anticancer therapy and as drugs interfering with 
the choline cycle may have varying efficacy in different breast cancer subtypes. 
Secondly, we found that the glycolytic rate is not directly associated with tumor 
growth rate. The glycolytic rate is higher in the slowly growing luminal-like 
xenografts, due to higher expression of genes involved in glycolysis. This illustrates 
the importance of microenvironmental regulation of tumor metabolism. Finally, we 
have shown how metabolic profiles represent the expression of genes directly 
involved in metabolic pathways.   
 
Using DCE-MRI, we have also shown how differences in angiogenesis and vascular 
function can be imaged using a clinically relevant contrast agent. The basal-like 
xenografts are better vascularised due to higher angiogenic activity, which is reflected 
in higher Ktrans and ve values than the luminal-like xenografts. The differences in 
vascular function and angiogenesis are relevant for interpretation of response to 
bevacizumab therapy. In contrast to classic chemotherapy (doxorubicin), 
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bevacizumab has a blood vessel-specific effect, leading to improved perfusion (and 
contrast enhancement) in central regions of the xenograft tumors. It was also found 
that bevacizumab therapy reduced both MVD and pMVD in basal-like xenografts. 
Combining these two data sets, it was concluded that bevacizumab both reduces 
angiogenic activity and normalises vascular function. However, DCE-MRI primarily 
reflects the vascular function and not the number of blood vessels. We also 
demonstrated that response to bevacizumab therapy was reflected by DW-MRI, which 
potentially also could be used for clinical therapy monitoring.  
 
The work presented in the thesis provides a solid fundament for further studies of 
differential response to therapy in these experimental models of breast cancer, and the 
use of MRI/MRS for early evaluation of response to therapy. Of special interest is the 
metabolic response to drugs targeting oncogenic signaling or metabolic pathways, 
which hopefully can be of benefit for patients with basal-like breast cancer. 
Development of methods for functional analysis of metabolic pathways using 13C HR 
MAS MRS can bridge the gap between current global metabolomic approaches and 
the development of 13C-enhanced tracers for clinical hyperpolarized MRSI. In 
addition, the thorough description of vascularity in these xenograft models may be 
useful in development of nanoparticulate contrast agents targeting angiogenic 
markers. 
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Distinct choline metabolic profiles are associated
with differences in gene expression for basal-like
and luminal-like breast cancer xenograft models
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Abstract
Background: Increased concentrations of choline-containing compounds are frequently observed in breast
carcinomas, and may serve as biomarkers for both diagnostic and treatment monitoring purposes. However,
underlying mechanisms for the abnormal choline metabolism are poorly understood.
Methods: The concentrations of choline-derived metabolites were determined in xenografted primary human
breast carcinomas, representing basal-like and luminal-like subtypes. Quantification of metabolites in fresh frozen
tissue was performed using high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS
MRS).
The expression of genes involved in phosphatidylcholine (PtdCho) metabolism was retrieved from whole genome
expression microarray analyses.
The metabolite profiles from xenografts were compared with profiles from human breast cancer, sampled from
patients with estrogen/progesterone receptor positive (ER+/PgR+) or triple negative (ER-/PgR-/HER2-) breast cancer.
Results: In basal-like xenografts, glycerophosphocholine (GPC) concentrations were higher than phosphocholine
(PCho) concentrations, whereas this pattern was reversed in luminal-like xenografts. These differences may be
explained by lower choline kinase (CHKA, CHKB) expression as well as higher PtdCho degradation mediated by
higher expression of phospholipase A2 group 4A (PLA2G4A) and phospholipase B1 (PLB1) in the basal-like model.
The glycine concentration was higher in the basal-like model. Although glycine could be derived from energy
metabolism pathways, the gene expression data suggested a metabolic shift from PtdCho synthesis to glycine
formation in basal-like xenografts. In agreement with results from the xenograft models, tissue samples from triple
negative breast carcinomas had higher GPC/PCho ratio than samples from ER+/PgR+ carcinomas, suggesting that
the choline metabolism in the experimental models is representative for luminal-like and basal-like human breast
cancer.
Conclusions: The differences in choline metabolite concentrations corresponded well with differences in gene
expression, demonstrating distinct metabolic profiles in the xenograft models representing basal-like and luminal-
like breast cancer. The same characteristics of choline metabolite profiles were also observed in patient material
from ER+/PgR+ and triple-negative breast cancer, suggesting that the xenografts are relevant model systems for
studies of choline metabolism in luminal-like and basal-like breast cancer.
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Background
Optimal treatment of individual breast cancer patients is
still a major challenge in oncology. An approach to
improve and individualize the treatment beyond the
markers and stratification tools used at present, is
through molecular subtyping of breast cancer [1]. Based
on variation in gene expression profiles, five molecular
subtypes have been identified [1-3]. The gene expression
patterns of these subtypes are similar across multiple
samples from the same tumor, shows no treatment-
related changes and have been reproduced in a number
of patient populations [2-7]. However, the current use
of these molecular subgroups in clinical practice
remains limited. Further understanding of the differ-
ences in biology between the various subtypes is needed
in order to predict therapeutic response and provide
individual treatment strategies based on gene expression
profiles [8].
Elevated levels of choline metabolites is a known fea-
ture of breast cancer, and it has been shown that drugs
targeting choline metabolism have selective in vivo and
in vitro cytotoxic efficacy against a variety of cancer
types [9-13]. Magnetic resonance spectroscopy (MRS) is
a valuable tool for studies of choline metabolism both in
patients and in experimental systems [14]. High resolu-
tion magic angle spinning (HR MAS) MRS of ex vivo
tissue samples has been particularly useful, as it allows
assessment of individual choline metabolites in intact
tissue specimens. Increased concentrations of choline,
phosphocholine (PCho) and glycerophosphocholine
(GPC) has been demonstrated both in cultured breast
cancer cells [15-17] and in human breast cancer biopsies
[18-21]. It has also been shown that choline metabolism
is altered following chemotherapy, suggesting the possi-
bility of using MRS for therapy monitoring [22-24].
However, to utilize these findings in diagnosis and indi-
vidualized therapy monitoring of breast cancer patients,
a better understanding of the choline metabolism
abnormalities on a molecular level is needed.
Several studies investigating expression of genes
involved in metabolism of phosphatidylcholine (PtdCho)
have been performed using breast cancer cell lines
[16,17,25,26]. PtdCho is an important cellular membrane
lipid, and this metabolic pathway directly involves cho-
line, PCho and GPC. In addition, genes involved in
transmembrane choline transport and conversion of
choline to glycine have been suggested to be important
for the observed choline concentrations in breast cancer
cells [16,27]. The choline metabolism profiles observed
in cultured breast cancer cells are more homogenous
than those seen in human biopsies. In order to bridge
the gap between in vitro research and clinical breast
cancer, there is a great need for animal models
representing different types of breast cancer for use in
functional and mechanistic studies. Serial orthotopic
transplantation of clinical tumor isolates in immunodefi-
cient mice is considered a promising tool for investiga-
tion of human breast cancer biology [28]. Establishment
of relevant experimental models of basal-like breast can-
cer is especially important both in order to understand
the special characteristics of this subtype, to find poten-
tial new molecular targets for therapy and to establish
potential biomarkers for monitoring response to
therapy.
The aim of this study was to compare the choline
metabolite patterns in animal models of basal-like and
luminal-like subtypes of breast cancer, and to study the
expression of genes related to choline metabolism in
order to explain the differences between the two breast
cancer subtypes. The two orthotopic xenograft models
used, MAS98.12 and MAS98.06, represent basal-like and
luminal-like subtypes of breast cancer, respectively [29].
Both models have been established by direct inoculation
of primary human tumor material into immunodeficient
animals. The content of creatine, choline, PCho, GPC,
taurine and glycine in the xenografts as well as human
breast cancer tissue samples was determined using HR
MAS MRS. The molecular basis of the observed differ-
ences in choline metabolism was studied using gene
expression microarray data. In order to evaluate if the
xenograft models are representative for human disease,
the metabolic profiles were compared to corresponding
profiles from patients with ER+/PgR+ or triple negative
breast cancer.
Methods
Animal model
The MAS98.12 and MAS98.06 tumor models were
established by orthotopic implantation of biopsy tissues
from primary mammary carcinomas in SCID mice as
previously described [29]. Both the primary carcinomas
and the xenograft models have been characterized using
gene expression profiling. These analyses demonstrated
that the primary carcinomas could be classified as lumi-
nal-like and basal-like subtypes of breast cancer, and
that these molecular subtypes were retained in the
MAS98.06 (luminal-like) and MAS98.12 (basal-like)
xenografts. Relevant characteristics of the models are
presented in Table 1. The tumors are serially trans-
planted. Tissue used for HR MAS MRS was from pas-
sage 47 (MAS98.12) and 28 (MAS98.06), and tissue
used for RNA microarray analysis was from passage 45
(MAS98.12) and 25 (MAS98.06).
The animals were kept under pathogen-free condi-
tions. Housing conditions included temperature between
19°C and 22°C, humidity between 50% and 60%, 20 air
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changes/hr and a 12 hr light/dark cycle. The animals
were fed RM1 diet (Scanbur BK, Norway) and distilled
tap water ad libitum. The drinking water was supple-
mented with 17-b-estradiol at a concentration of 4 μg/
ml in order to ensure stimulation of the estrogen recep-
tors and promote tumor growth in the MAS98.06 xeno-
grafts. With respect to tumor growth rate, this estrogen
supplement correspond to the use of s.c. continuous
release 17-b-estradiol pellets (1.7 mg/pellet), which were
used during establishment of the animal models [29].
To provide equal experimental conditions, the
MAS98.12 xenografts also received estradiol supplement.
This could in theory cause non-ER-mediated effects on
choline metabolite profile. However, the similarities
between human tissue samples and xenograft tissue sug-
gest that such effects are insignificant in ER-breast
cancer.
Following sacrifice by cervical dislocation, tumor tis-
sue was harvested from 10 animals from each model for
the HR MAS MRS analyses and for 6 animals from each
model for gene expression microarray analyses, at tumor
diameters of approximately 13-15 mm. Samples were
put in cryogenic vials and immersed in liquid nitrogen
immediately after dissection and stored under cryogenic
conditions until analysis. All procedures and experi-
ments involving animals were approved by The National
Animal Research Authority, and carried out according
to the European Convention for the Protection of Verte-
brates used for Scientific Purposes.
Human tissue samples
For comparison of xenograft models with human breast
cancer tissue, biopsies from 22 breast cancer patients
were identified in our internal database based on histo-
pathology/immunohistochemistry data. Patients with
either ER+/PgR+ (n = 14) or triple negative (n = 8)
phenotype were included. Biopsy material was obtained
during surgery and immediately frozen in liquid nitro-
gen. Histopathology and immunohistochemistry data for
the selected patients was obtained from hospital records.
Patient and tumor characteristics are presented in Table
2. The biopsy material was subject to HR MAS MRS
analysis and subsequent histopathological evaluation
using hematoxylin/eosin (HE) staining. The use of
patient material was approved by the Regional Commit-
tee for Medical and Health Research Ethics, and
informed written consent was obtained from all
included patients.
HR MAS MRS of xenograft tissue
Storage time before HR MAS MRS analysis was less
than one month for all 20 samples. Macroscopically
viable tumor tissue was cut to fit a 30 μl disposable
insert (Bruker Biospin Corp.), prefilled with 3 μl PBS
made on D2O containing 98.8 mM trimethylsilyltetra-
deuteropropionic acid (TSP) for chemical shift referen-
cing. The average sample weight was 15 ± 3 mg (mean
± SD). HR MAS MR spectra were recorded using a Bru-
ker AVANCE DRX600 spectrometer equipped with a
1H/13C HR MAS probe (Bruker BioSpin Corp.). Samples
were spun at 5 kHz with an instrumental temperature
setting of 4°C. A pulse-acquired experiment including
the ERETIC sequence (ereticpr.drx; Bruker) was per-
formed for all samples. The ERETIC signal was posi-
tioned at -1.0 ppm. The water resonance was saturated
for 15 seconds (60 dB continuous wave), followed by a
60-degree pulse for excitation. Signals were collected
over a sweep width of 16.7 ppm. 128 FIDs were
acquired into 64K points during 3.28 seconds. Spectra
were Fourier transformed into 128K after 0.3 Hz expo-
nential line broadening and chemical shifts were cali-
brated to the TSP singlet at 0 ppm. Spectral
Table 1 Summary of xenograft characteristics
Basal-like xenograft (MAS98.12) Luminal-like xenograft (MAS98.06)
Primary tumor Xenograft Primary tumor Xenograft
Tumor grade Grade III IDC NA Grade III IDC NA
Lymph node status No metastasis NA Metastasis to 12 of 25 nodes NA
No distant metastases
Differentiation Poorly differentiated Poorly differentiated Well differentiated Poorly differentiated
Hormone receptor status ER-/PgR+** ER-/PgR- ER+/PgR+ ER+/PgR+
ERBB2 amplification* Negative Negative Negative Negative
Intrinsic molecular subtype Basal-like Basal-like Luminal-like Luminal-like
TP53 status Wildtype Mutated Mutated Mutated
Volume doubling time NA 1-2 days NA 7 days
Proliferation index (Ki67) Missing 28% Missing 35%
Summary of characteristics related to genotype and phenotype of the xenograft models
* Measured at the DNA level by array Comparative Genomic Hybridization (aCGH)
** The primary basal-like carcinoma had very weak cytoplasmic staining for PgR29.
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assignments were performed based on a previous HR
MAS MRS study of breast cancer lesions [30]. One HR
MAS MRS spectrum from the MAS98.06 animals was
lost due to technical error.
The regions from 0.20 to -0.20 ppm (TSP), -0.85 to
-1.15 ppm (ERETIC) and 3.60 to 2.90 ppm (glycine,
taurine, GPC, PCho, choline, and creatine) were selected
for quantification in all spectra. Peak areas were calcu-
lated by curve fitting (PeakFit v 4, Systat Software Inc)
using a combination of Gaussian and Lorentzian line-
shapes (Voigt function). The correlation coefficient of
the fit (r2) was > 0.95 for all spectra. The ERETIC signal
was quantified to 3.17 × 10-7 moles using a series of
creatine calibration standards as previously described
[31]. Concentrations of tissue metabolites ([MET]) were
calculated relative to the ERETIC signal using equation
(1):
[ ]MET
A
A k
n
m
MET
ERETIC MET
ERETIC
sample
= × ×
1
(1)
AMET and AERETIC are the calculated areas of the
metabolite and the ERETIC signals, respectively; kMET is
the number of protons giving rise to the metabolite sig-
nal; nERETIC is the number of moles the ERETIC signal
represents; and msample is the mass of the sample. The
metabolite concentrations measured using the ERETIC
signal were compared using a 2-sided Student’s t-test
with a significance level of p < 0.05 using Sigmaplot
11.0 (Systat Software Inc.).
HR MAS MRS of human tissue samples
Human tissue samples were prepared for HR MAS MRS
analysis using the same procedure as the xenograft sam-
ples. Spectra were acquired using a spin-echo Carr-Pur-
cell-Meiboom-Gill sequence (cpmgpr; Bruker) with 2 s
water suppression prior to a 90° excitation pulse. The
spin-echo sequence for suppression of broad peaks was
performed using a delay of 1 ms repeated 136 times,
resulting in an effective echo time of 285 ms. A total of
128 scans over a spectral region of 10 kHz were col-
lected into 32k points during 1.64 s. The spectra were
Fourier transformed into 128 K after 0.3 Hz exponential
line broadening, and the metabolite region from 3.60 to
3.00 ppm was selected for further evaluation. The spec-
tra were normalized by scaling the spectral data of all
samples to achieve an equal total area for each spec-
trum. Metabolite peak areas were then obtained by
curve fitting as described above.
Histopathology
Following HR MAS MRS analysis, the xenograft samples
were fixed in 10% neutral buffered formalin and
embedded in paraffin. One histopathological section
were prepared from each sample, stained with hematox-
ylin/eosin/saffron (HES) according to standard protocol
and evaluated microscopically. A visual evaluation with
respect to the presence of viable tumor tissue and the
extent of necrosis was performed. Tumor grade, hor-
mone receptor status and HER2 expression of human
tissue samples was obtained from hospital records. In
addition, specimens analysed by HR MAS MRS were
HES-stained and the relative areas of normal and neo-
plastic epithelial tissue, necrotic tissue, fat and fibrous
connective tissue were scored.
Gene expression analysis
Gene expression analysis was performed on tumor tis-
sue from 6 animals from each of the two xenograft
models, using a one-color microarray-based platform
(Agilent). Total RNA was isolated from snap frozen
tumor tissue using TRIzol (Invitrogen) and resus-
pended in RNase-free water. Total RNA (700 ng) was
amplified, labelled with Cy3, and 1.65 μg cRNA was
hybridized to 4 × 44 k Agilent Whole Human Genome
Oligo Microarrays at 60°C and 10 rpm for 17 hours,
according to the manufacturer’s protocol. The arrays
were scanned using an Agilent G2565A DNA microar-
ray scanner and extracted using Feature Extraction (v
10.1.1.1, Agilent). One microarray from the MAS98.06
model was removed due to poor array quality. The
microarray data was normalized and analysed using R
(v 2.9.0) and the LIMMA Bioconductor package [32].
The raw signals were corrected for multiplicative
detrending effects and the arrays were quantile nor-
malized and log2 transformed. Probes which were
flagged as outliers by the Feature Extraction software
or were present in less than 30% of the samples, were
removed. The signal intensities were averaged between
duplicate probes, and the probe with the highest inter-
quartile range was selected to represent each unique
transcript.
Table 2 Summary of patient characteristics
Subtype n Patient age
(years)
Phenotype Tumor
grade1/2/3
Tumor size
(cm)
Mean tumor
fraction (%)
Mean connective tissue
fraction (%)
Mean fatty tissue
fraction (%)
ER+/PgR+ 14 57 ± 16 ER+/PgR+ 1/10/3 2.3 ± 1.3 23 ± 11 72 ± 11 5 ± 7
Triple
negative
8 57 ± 17 ER-/PgR-/
HER2-
0/3/5 2.2 ± 1.0 38 ± 32 55 ± 31 6 ± 7
Summary of patient and sample characteristics of the different subgroups of human tissue samples (mean ± SD)
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A total of 119 genes were selected for further analysis.
The selection criteria were a) genes involved in KEGG
homo sapiens glycerophospholipid pathway hsa:00564
[33], or b) genes coding for proteins reported to be
directly involved in choline transport and choline and
glycine metabolism [16,34-36]. Of the selected genes,
117 were represented on the microarray (full gene list
supplied as additional file 1).
Testing for differential expression between the xeno-
graft models was performed using t-tests with Empirical
Bayesian correction of the test statistics [32]. To account
for multiple testing, an adjusted p-value of 0.05 (using
Benjamini & Hochberg’s false discovery rate) was
defined as the threshold for significant differential
expression between the xenograft models. The microar-
ray data from the significantly differentially expressed
genes was centered across genes and clustered across
genes and samples using hierarchical clustering with
Euclidian distance and complete linkage. The relation-
ship between gene expression and metabolite concentra-
tions was explored using Ingenuity Pathways Analysis
(Ingenuity Systems), and an illustration was adapted
from the canonical Glycerophospholipid Metabolism
and Glycine, Serine and Threonine Metabolism path-
ways [33]. The abovementioned gene list was also
extracted from microarray data from previously
described passages of the same xenograft models [29],
to ensure that gene expression remain stable throughout
serial transplantation of the xenografts.
Results
Histopathology
All xenograft samples were found to contain mainly
viable tumor tissue and stromal connective tissue,
shown previously to be recruited mouse stromal tissue
[29], with negligible necrosis (< 10% area) in 18 of 19
samples. The HR MAS MRS data was therefore consid-
ered to be representative of the metabolite concentra-
tions in the solid tumors. One sample in the MAS98.06
group contained a necrotic area, microscopically esti-
mated to 25% area of the specimen. However, the meta-
bolite concentrations measured in this sample differed
from the group mean by less than ± 2 SD, and the sam-
ple was therefore not excluded from the data set. The
mean fractions of tumor and connective tissue in the
human tissue samples are presented in Table 2.
HR MAS MRS of xenograft samples
The HR MAS MRS analyses revealed several significant
differences in the metabolic profiles of the two xenograft
models. Mean 1H HR MAS MRS spectra from the two
models are shown in Figure 1 (spectral region 3.6 - 3.0
ppm). The metabolites assigned in Figure 1 were quanti-
fiable in all spectra. The metabolite concentrations
calculated using the ERETIC reference signal are pre-
sented in Table 3. There was no significant difference in
choline concentration between the models. However,
the concentrations of GPC and PCho were significantly
higher than the choline concentration in both the basal-
like and the luminal-like model. While all the samples
from basal-like xenografts showed higher concentration
of GPC than PCho, the samples from luminal-like xeno-
grafts invariably showed lower concentrations of GPC
than PCho. The differences in GPC and PCho concen-
trations between the two xenograft models were statisti-
cally significant (p < 0.001 and p < 0.01, respectively).
The concentration of glycine was significantly higher in
the basal-like than in the luminal-like model (p < 0.002).
HR MAS MRS of human tissue samples
The HR MAS MRS spectra from the tissue samples
were retrieved from our internal database, and mean
spectra from the two groups are shown in Figure 1. The
mean metabolite profiles demonstrated that triple nega-
tive breast cancer tissue had high GPC and low PCho
concentrations, whereas tissue from ER+/PgR+ patients
had low GPC and high PCho. There was a significant
difference in the GPC/PCho peak area ratio between ER
+/PgR+ and triple negative samples (0.8 ± 0.5 and 1.5 ±
0.7, respectively. p = 0.01), corresponding to the findings
from the xenograft models. The mean spectra from
human tissue samples also suggested that the glycine
concentration was higher in triple negative breast cancer
tissue samples. Using the glycine/total peak area ratio as
marker for glycine content, this trend was not statisti-
cally significant (p = 0.19). The relative choline peak
area was significantly higher in triple negative tissue
(p < 0.00003) and the relative creatine peak area was
significantly lower (p = 0.024).
Gene expression analysis of xenograft tissue
Of the 119 investigated genes, 67 were differentially
expressed between the xenograft models at a 5% adjusted
(false discovery rate) significance level. Microarray data
from earlier passages of the same xenograft models [29]
showed similar trends of differential expression (data not
shown). The complete results from the gene expression
analysis are available as additional file. A heatmap of the
differentially expressed genes is presented in Figure 2, with
hierarchical clustering of genes and samples. In the follow-
ing sections, only genes directly involved in synthesis and
degradation of PtdCho from choline are considered.
Among the five selected genes coding for proteins
known to be involved in transmembrane choline trans-
port, only solute carrier family 44, member 1 (SLC44A1)
showed significantly different expression between the
two models. The expression of this transporter, also
known as choline transporter-like protein 1 (CTL1), was
Moestue et al. BMC Cancer 2010, 10:433
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lower in basal-like than luminal-like xenografts. Solute
carrier family 22, member 1 (SLC22A1) and solute car-
rier family 44, member 2 (SLC44A2) were similarly
expressed in the two models, whereas solute carrier
family 5 (choline transporter), member 7 (SLC5A7) and
solute carrier family 22 (organic cation transporter),
member 2 (SLC22A2), were expressed below the limit of
detection. SLC5A7 is also known as choline transporter
1 (CHT1), a high-affinity choline-specific transporter
protein, whereas SLC44A2 is also known as choline-
transporter like protein 2 (CTL2).
Genes directly involved in choline metabolism which
were differentially expressed between the xenograft
models are listed in Table 4 and 5. A schematic
overview of intracellular choline metabolite concentra-
tions and the comparative gene expression (the anabolic
Kennedy pathway, PtdCho breakdown and conversion of
choline to glycine) between the xenograft models is pre-
sented in Figure 3. As shown in Figure 3, choline is con-
verted to PCho through the action of two isoforms of
the same enzyme, choline kinase alpha and beta. The
expression of the genes (CHKA, CHKB) coding for both
isoforms was significantly lower in the basal-like than in
the luminal-like model.
Conversion of PCho to CDP-choline is mediated
through the alpha and beta isoforms of phosphate cyti-
dylyl transferase 1 (PCYT1A and PCYT1B). The expres-
sion of PCYT1B was significantly higher, and PCYT1A
was significantly lower in the basal-like than the lumi-
nal-like model. The gene coding for choline phospho-
transferase 1 (CHPT1), which converts CDP-PCho to
PtdCho, had a significantly lower expression level in the
basal-like than in the luminal-like model.
PtdCho is degraded by several different phospholi-
pases. Enzymes in the phosphoplipase A2 group (PLA2)
convert PtdCho to acyl-GPC. Of the 13 PLA2 isoforms
studied, two were significantly higher expressed in the
basal-like model, three were significantly lower
expressed, five showed no significant difference in
expression and three were below the limit of detection.
Figure 1 Mean HR MAS MRS spectra from human tissue samples and xenograft tissue. HR MAS MRS spectra (spectral region 3.6 to 3.0
ppm) of ER+/PgR+ (top left) and triple negative (top right) human tissue samples, and luminal-like (bottom left) and basal-like (bottom right)
xenograft samples. Spectral assignments are provided for peaks used in quantification.
Table 3 Metabolite concentrations
MAS98.12 (n = 10) MAS98.06 (n = 9)
Creatine 4.1 ± 1.4 3.4 ± 1.7
Choline 1.2 ± 0.7 0.9 ± 0.6
Phosphocholine * 4.5 ± 2.1 9.1 ± 4.4
Glycerophosphocholine ** 9.8 ± 2.5 2.7 ± 1.7
Taurine 14.7 ± 4.1 19.1 ± 9.1
Glycine * 8.2 ± 3.0 4.0 ± 1.8
Metabolite concentrations in basal-like (MAS98.12) and luminal-like
(MAS98.06) xenografts calculated from HR MAS MRS spectra using the ERETIC
method (μmol/g, mean ± SD, * p < 0.01, ** p < 0.001)
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The largest difference in gene expression between the
two models was found for PLA2G4A, where a log2-fold
difference of 6.4 in gene expression was observed. Phos-
pholipase B1 (PLB1) is involved in both deacetylation
steps from PtdCho to GPC, and was significantly higher
expressed in the basal-like than in the luminal-like
model.
Phospholipase D, with the two isoforms PLD1 and
PLD2, converts PtdCho to choline. The expression of
PLD1 was significantly higher and the expression of
PLD2 was significantly lower in the basal-like compared
to the luminal-like model. Other genes related to the
degradation of PtdCho, such as lecithin-cholesterol acet-
yltransferase (LCAT) and phosphatidylserine synthase 1
(PTDSS1) also had significantly higher expression levels
in the basal-like than in the luminal-like model. The
GDPD5 gene, coding for glycerophosphodiester phos-
phodiesterase (GDPD) was significantly higher expressed
in the basal-like model than in the luminal-like model,
indicating that GPC degradation may occur at a higher
rate in basal-like xenografts. However, an isoform of this
gene, GDPD1, was higher expressed in the luminal-like
xenografts. As shown in Figure 3, choline dehydrogenase
(CHDH) mediates the irreversible conversion of choline
to betaine, which is a key precursor in the synthesis of
glycine. The expression of CHDH was significantly
higher in the basal-like than in the luminal-like model.
Sarcosine dehydrogenase (SARDH), involved in the con-
version of betaine to glycine, also had significantly
higher expression levels in the basal-like model.
Discussion
The HR MAS MRS data demonstrated significant differ-
ences in choline metabolite pattern between the basal-
like and luminal-like xenograft models. In particular, the
difference in GPC and PCho concentrations is an inter-
esting finding, as the pattern seen in the basal-like
model does not correspond to typical in vitro choline
metabolite patterns [15,17]. In addition, expression data
showed that several genes directly associated with cho-
line metabolism differed significantly between the two
models. Differences in expression of genes involved in
choline metabolism corresponded to differences in
metabolite concentrations, suggesting that transcrip-
tional differences between the models are reflected in
the HR MAS MRS spectra. The relative amounts of
GPC and PCho in human tissue samples from triple
negative and ER+/PgR+ subtypes of breast cancer corre-
sponded well with the data from the xenografts.
In order to evaluate if the choline metabolism in the
xenograft models is representative for basal-like and
luminal-like breast cancer in humans, they were com-
pared to data from triple negative and ER+/PgR+ breast
cancer patients. It is assumed that the triple-negative
Figure 2 Heatmap of differentially expressed genes in
xenograft models. Hierarchical clustering of the 67 differentially
expressed genes (false discovery rate < 0.05) involved in the KEGG
homo sapiens glycerophospholipid pathway hsa:00564, choline
transport or directly involved in conversion from choline to glycine
(Red: high expression compared to mean expression in xenograft
samples. Blue: low expression compared to mean expression in
xenograft samples). The microarray data was centred across genes
and clustered across genes and samples using Euclidian distance
and complete linkage.
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phenotype is a valid surrogate marker for basal-like
breast cancer, as approximately 90% of triple-negative
breast carcinomas can be classified as basal-like based
on the intrinsic molecular subtyping developed by Sørlie
et al [3,37]. On the other hand, expression of estrogen
and/or progesterone receptors is a typical feature of
luminal A and B subtypes, whereas the ERBB2 and
basal-like subtypes of breast cancer rarely express hor-
mone receptors [38,39]. Therefore, the ER+/PgR+ phe-
notype is considered to be a valid surrogate marker for
luminal-like subtypes of breast cancer.
Using gene expression profiling, the molecular causes
for the differences in choline metabolism was further
explored in the xenograft models. The heatmap of all 64
significantly differentially expressed genes in Figure 2,
clearly shows that different sets of genes related to
phospholipid metabolism are higher expressed the basal-
like model compared to the luminal-like models. This
indicates that the regulation of choline metabolism differ
between the two xenograft models. Although this study
does not provide data on metabolic flux, the methods
used are suitable for highlighting key steps in choline
metabolism. Comparison of these two disease models
does not, however, give any information with respect to
the difference between choline metabolism in normal
breast versus breast cancer tissue. Nevertheless, gene
expression profiling of the xenograft models showed sig-
nificant differences in the expression of genes directly
involved in choline metabolism, suggesting that these
genes may play key roles in regulation of choline meta-
bolite concentrations in human breast cancer.
Increased choline transport has been associated with
the abnormally high concentrations of PCho observed in
breast cancer [16,27,40]. In our study, the influx of cho-
line in the two models could not be fully evaluated from
the gene expression data, as only one of five investigated
Table 4 Differentially expressed genes
Entrez
ID
Probe name Gene
name
Encoded protein Log2-fold
difference
Adjusted p-value (false
discovery rate)
5321 A_23_P11685 PLA2G4A Phospholipase A2, group IV A 6.4 4.4E-16
55349 A_23_P69293 CHDH Choline dehydrogenase 3.3 4.0E-13
1757 A_24_P35400 SARDH Sarcosine dehydrogenase 2.5 7.6E-12
9468 A_24_P941353 PCYT1B Phosphate cytidylyltransferase 1, choline, beta 1.7 3.7E-9
31896 A_23_P87401 GDPD5 Glycerophosphodiester phosphodiesterase domain
containing 5
1.0 4.2E-6
8681 A_23_P403424 PLA2G4B Phospholipase A2, group IV B 0.9 9.8E-5
9791 A_23_P168868 PTDSS1 Phosphatidylserine synthase I 0.9 9.6E-7
10434 A_23_P19192 LYPLA1 Lysophospholipase 1 0.9 0.001
3931 A_23_P218237 LCAT Lecithin-cholesterol acyltransferase 0.8 0.0002
151056 A_23_P56356 PLB1 Phospholipase B1 0.7 0.0001
5337 A_23_P155335 PLD1 Phospholipase D1 0.7 0.0005
Genes directly involved in choline metabolism with significantly higher expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors
Table 5 Differentially expressed genes
Entrez
ID
Probe name Gene
name
Encoded protein Log2-fold
difference
Adjusted p-value (false
discovery rate)
50487 A_23_P17814 PLA2G3 Phospholipase A2, group III -3.1 1.1E-12
81579 A_23_P30020 PLA2G12A Phospholipase A2, group XII A -1.6 2.5E-9
56994 A_23_P105571 CHPT1 Choline phosphotransferase 1 -1.4 1.6E-7
23446 A_23_P216630 SLC44A1 Solute carrier family 44, member 1 (CTL1) -1.1 7.9E-7
5338 A_23_P4308 PLD2 Phospholipase D2 -1.1 1.2E-6
8399 A_23_P88767 PLA2G10 Phospholipase A2, group X -1.1 3.1E-6
1119 A_23_P314120 CHKB Choline kinase beta -0.8 2.0E-6
11313 A_24_P276490 LYPLA2 Lysophospholipase II -0.4 0.005
5130 A_23_P252681 PCYT1A Phosphate cytidylyltransferase 1, choline, alpha -0.4 0.035
24657 A_23_P84666 GDPD1 Glycerophosphodiester phosphodiesterase domain
containing I
-0.4 0.005
1119 A_23_P124742 CHKA Choline kinase, alpha -0.3 0.047
Genes directly involved in choline metabolism with significantly lower expression in basal-like (MAS98.12) than luminal-like (MAS98.06) tumors
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choline transporters was differentially expressed. Choline
transport has been shown to be less important than
PtdCho turnover for total choline metabolite concentra-
tions [17]. Differences in choline uptake may still have
impact on the choline metabolite concentrations, and
specific studies using isotopically labelled choline could
possibly allow accurate evaluation of choline transport
rate in the two xenograft models.
In breast cancer cells, the intracellular metabolism of
choline is divided in two major pathways as shown in
Figure 3: Betaine production or PtdCho synthesis
[27,34]. In the betaine synthesis pathway, choline is oxi-
dized to betaine through the action of choline dehydro-
genase (CHDH). Betaine is then demethylated to glycine.
In vitro studies of MCF7-cells have shown that PtdCho
synthesis is the pathway predominantly accountable for
choline turnover [34]. The first step in the PtdCho
synthesis pathway is the phosphorylation of choline
through choline kinase, yielding PCho (Figure 3). It has
been shown that increased expression of CHKA is
Figure 3 Differences in gene expression and metabolite concentrations. Differences in intracellular choline metabolism, choline transport
and glycine formation between basal-like and luminal-like xenografts. Red: higher gene expression/metabolite concentration in basal-like
xenografts. Blue: higher gene expression/metabolite concentration in luminal-like xenografts. White: Non-significant difference in expression/
concentration. Log2-fold difference between models is indicated by color intensity. Only significantly differentially expressed genes are illustrated
at each EC number, which represents specific enzymatic reactions. The metabolites which were measured with HR MAS MRS are outlined with a
thicker line.
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critical for proliferation both of mammary epithelial
cells and breast cancer [41], but in vitro studies of dif-
ferent breast cancer cell lines have not conclusively
demonstrated a correlation between CHKA expression
and PCho concentration [16,26]. In our study, the
expression of CHKA and CHKB was significantly lower
in the basal-like than in the luminal-like model,
although some variability in expression was observed
(Figure 2). This is consistent with the lower PCho con-
centrations measured in the basal-like model. Betaine
production is thought to contribute only slightly to the
overall conversion of choline, and neither choline trans-
port nor GPC degradation is conclusive with respect to
their contribution to the choline pool. As normal breast
tissue or benign breast lesions rarely exhibit increased
choline metabolite levels, the xenograft models are
believed to represent typical choline metabolism
abnormalities of breast carcinomas [42,43]. Therefore, it
should be stressed that CHKA and CHKB expression is
likely to be upregulated in both xenograft models com-
pared to normal breast tissue. The lower PCho concen-
trations in the basal-like xenografts may also in part be
a result of higher CHDH expression. This suggests that
conversion of choline to betaine is upregulated, shifting
the metabolic flux in favour of glycine formation.
SARDH, related to conversion of betaine to glycine, was
also significantly higher expressed in the basal-like
model. The concentration of glycine in the basal-like
model was indeed higher than in the luminal-like
model, suggesting that there is a difference in choline
routing and glycine production between the two breast
cancer subtypes. An association between tumor aggres-
siveness and glycine concentration has been noted also
in clinical breast cancer tissue biopsies [21]. Abnormal-
ities in cancer energy metabolism are widely recognized,
and differences in glycine concentration between the
two xenograft models in this study could well be an
indirect result of this phenomenon.
Degradation of PtdCho is the primary source of GPC.
The expression of PLA2G4A, PLA2G4B, LCAT, LYPLA1
and PLB1, which all are associated with this pathway, was
higher in the basal-like model. Other genes (PLA2G3,
PLA2G12A, PLA2G10, LYPLA2) were lower expressed in
the basal-like model, and a clear association between
PtdCho degradation and GPC concentration could not
be concluded. However, in vitro studies have suggested
that GPC concentrations are associated with PLA2G4A
levels, which is consistent with our findings [17]. A lower
rate of GPC degradation could account for the higher
GPC concentration observed in the basal-like xenograft
model. The expression of GDPD5 was, however, higher
in basal-like xenografts. The observed differences
between the two models in the relative expression of dif-
ferent genes assigned to the abovementioned enzymatic
steps could be reflecting the relative importance of differ-
ent gene products coding for proteins with the same
enzymatic activity in the two models.
By associating choline metabolite concentrations with
tumor cell phenotype, it has been proposed that PCho con-
centration increase with the malignancy of the tumor cell
line when grown in culture [15]. However, other in vitro
studies have failed to show a correlation between malig-
nancy and choline metabolite concentrations [16]. It has
been suggested that differences in experimental design,
particularly the stage of cell growth, are accountable for
these discrepancies [26]. In all the abovementioned in vitro
studies of breast cancer cells, PCho concentrations were
significantly higher than GPC concentrations. However,
both in xenograft models of breast cancer and in clinical
tissue samples, GPC concentrations higher than PCho con-
centrations have been observed [21,44]. GPC concentration
has been shown to be negatively correlated with estrogen
receptor content in breast carcinomas, which agrees with
the relatively high GPC content in the basal-like xenograft
[45]. Our data show that GPC concentration is significantly
lower and PCho concentration is significantly higher in the
luminal-like animal model, which represents a less aggres-
sive disease than the basal-like model. This suggests that
the relationship between choline metabolite concentrations
and malignancy of solid tumors is more complex than indi-
cated by studies of breast cancer cell lines. Discrepancies
between in vitro data and clinical data may be attributed to
the microenvironment of solid tumors. It has recently been
shown that the metabolic profiles change when the same
breast cancer cell lines are studied both in vitro and in vivo
[46]. In addition, in vitro simulation of microenvironmental
factors in solid tumors has demonstrated that PCho and
GPC concentrations respond to changes in acidity, oxyge-
nation level and glucose accessibility [44].
The relevance of the basal-like and luminal-like xeno-
grafts used in this study was further supported by com-
paring the choline metabolite pattern with that of
human tissue samples from ER+/PgR+ and triple nega-
tive breast cancer. Evaluation of metabolite levels
through relative peak areas demonstrated that the mean
GPC/PCho ratio was significantly higher in triple nega-
tive breast cancer than in ER+/PgR+ breast cancer. The
relative PCho area was significantly higher in ER+/PgR+
samples than in samples from triple negative breast can-
cer. A trend towards higher glycine concentration was
also found in triple negative tissue samples. Interest-
ingly, the choline concentration in triple negative breast
cancer was higher than in ER+/PgR+ breast cancer.
Overall, the striking similarity between xenografts and
human tissue samples with respect to GPC and PCho
levels suggest that the xenografts have maintained
genetic and/or microenvironmental features from the
primary carcinomas which are relevant for the choline
Moestue et al. BMC Cancer 2010, 10:433
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metabolite pattern. The spectra from human tissue sam-
ples also suggest that PCho concentrations alone are not
a reliable prognostic biomarker. The triple negative sam-
ples represent disease with poor prognosis, yet the PCho
level in these samples appear to be significantly lower
than in ER+/PgR+ samples. This finding encourages
large-scale studies of the metabolite pattern and gene
expression in the different molecular subtypes of breast
cancer, as this may reveal new drug targets or suggest
strategies for individualised therapy using drugs target-
ing the choline metabolism pathways.
When interpreting the gene expression data from the
two xenograft models, it should be kept in mind that
gene expression not always represents the actual enzy-
matic activity. Isoforms of the same enzyme may exhibit
differences in transcriptional regulation, and mRNA
concentrations do not account for post-translational
modification of enzymes. In addition, the concentrations
of all investigated choline-containing compounds are
determined by more than one metabolic reaction. Thus,
a simplistic model for correlating gene expression with
metabolite concentration is not applicable. The net rate
of all relevant metabolic reactions governs the metabo-
lite concentrations, and the relative importance of each
metabolic reaction is unknown. This must be kept in
mind when interpreting the data. However, the gene
expression data provide significant information in terms
of highlighting the reactions that are most likely to be
relevant for the observed differences in metabolic pat-
tern. Hypotheses generated on the basis of microarray
data should be evaluated by tracking the flux of metabo-
lites through the different pathways.
Comparing our data with pre-existing studies of cho-
line metabolism in cultured cells and in vivo models with
data from human biopsies, we suggest that primary
tumor xenografts are more relevant model systems than
cell cultures with respect to investigation of metabolic
profiles in different breast cancer subtypes, and may be a
better approach to studies of therapeutic efficacy in the
different breast cancer subtypes. As the choline metabo-
lite profile of the xenograft models used in the study
appear representative of basal-like and luminal-like
human breast cancer, the models are considered valuable
tools for testing of targeted drugs and for monitoring
response to treatment in these subtypes of breast cancer.
Conclusions
HR MAS MRS analyses of a basal-like and a luminal-like
xenograft model demonstrated significant differences in
choline metabolite concentrations. In the more aggressive
basal-like tumor, GPC concentrations were higher than
PCho concentrations, whereas this pattern was reversed in
the luminal-like model. Glycine concentration was also
significantly higher in the basal-like model. These
differences could at least in part be explained by lower
choline kinase expression and increased PtdCho degrada-
tion in the basal-like model. The gene expression data also
suggested a possible shift in metabolic flux from PtdCho
synthesis to glycine formation in the basal-like model. The
choline metabolism pattern in the xenografts corre-
sponded well with spectra from tissue samples from triple
negative and ER+/PgR+ human breast carcinomas, sug-
gesting that the basal-like and luminal-like xenografts may
be a relevant model system for studies of choline metabo-
lism in these two subtypes of human breast cancer.
Additional material
Additional file 1: Differential gene expression. Excel spreadsheet
containing results from the differential gene expression analysis of the
119 investigated genes.
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